DE102015121607A1 - Composition for the treatment of colds and allergies - Google Patents

Abstract

The present invention relates to a composition, in particular a pharmaceutical composition, which is preferably suitable for use in the prophylactic and / or therapeutic treatment of respiratory diseases, especially colds and / or allergies, and on the one hand at least one active against colds and / or allergies homeopathic active substance and on the other hand contains at least one mucus drug and / or at least one mucilage.

Description

The present invention relates to the field of treatment of respiratory diseases, in particular colds and / or allergies.

In particular, the present invention relates to a composition which is suitable for the prophylactic or therapeutic treatment of respiratory diseases, in particular of common colds or of allergies. Moreover, the present invention relates to the use of this composition according to the invention.

The term respiratory tract, synonymously also referred to as respiratory tract or respiratory apparatus, is usually understood to mean the entire system of the organs which serve respiration. The airways are divided into the upper sections, which include the nasal cavity with its sinuses and the throat, and the lower airways, which are the larynx, the trachea, and the entire branch of the bronchial tree, i. H. also include the lungs, divided.

The respiratory tract can be affected by diseases of various causes. Most commonly, respiratory diseases are based on inflammatory, infectious or allergic processes or even combinations of several of the aforementioned causes. Commonly occurring respiratory diseases include in particular respiratory infections, such as influenza infections or colds, bronchitis and pneumonia, respiratory allergic diseases, especially allergic cold or asthma, and chronic obstructive airway diseases.

Respiratory diseases often show similar symptoms, regardless of the underlying cause. In particular, symptoms such as runny nose, coughing, irritation of the mucous membranes and swollen mucous membranes on the pharynx, in the nose and on the eyes, hoarseness and impaired breathing are associated with the abovementioned disorders. In addition, fever, headache and general malaise may also accompany the symptoms.

Although respiratory disease is one of the most common causes of physician visits in the Western population, the previously known therapeutic approaches for relieving the symptoms associated with respiratory disease are often unsatisfactory, as explained in detail below.

For the treatment of runny nose, both of infectious colds and allergic rhinitis, usually decongestant nasal sprays based on vasoconstrictors, in particular alpha-sympathomimetics, are used, which, however, are often associated with serious side effects. In particular, the nasal mucosa dries out and it can come to certain habituation effects to dependency. In addition, the vasoconstrictor effect can lead to serious systemic side effects, such as reduced blood flow. By contrast, the herbal nasal sprays known in the prior art are better tolerated, but have no good activity.

Furthermore, mucolytic coughs or cough syrups are often used for the treatment of respiratory diseases, which, however, often do not lead to the desired success or which have no satisfactory efficacy. In particular, inflammation and often associated with respiratory diseases pain symptoms can be based on this often insufficient relief. Similarly, with well-known home remedies, such as gargle solutions, cold steels or chamomile steam baths, achieved in the treatment of respiratory diseases no satisfactory therapeutic success.

The medicaments or compositions customarily used for the treatment of, in particular, allergic respiratory diseases are also not optimal, in particular with regard to their side-effect profile. For example, corticosteroid-based drugs can lead to side effects such as obesity, increased blood pressure and edema or water retention. The antihistamines used in particular in the treatment of allergic rhinitis can lead to unpleasant side effects, such as severe tiredness.

Against the background of the above-described problems of the prior art, the present invention therefore has for its object to provide a composition which is suitable for the treatment of respiratory diseases, especially colds and / or allergies, and which at least largely avoids or at least mitigates the previously described disadvantages of the prior art.

In particular, a composition is to be provided which, in the context of the treatment of respiratory diseases, in particular colds and / or allergies, has an improved efficacy, in particular with regard to the alleviation of inflammation, pain, irritated mucous membranes and allergic-related complaints, and, moreover, an improved side-effect profile having.

To achieve the object described above, the present invention proposes - according to the first aspect of the present invention - a composition according to claim 1; Further, particularly advantageous embodiments of the composition according to the invention are the subject of the relevant subclaims.

Furthermore, the present invention - according to a further aspect of the present invention - is based on the use according to the invention of compositions according to the present invention, as defined in the relevant claim for use.

It goes without saying that embodiments, embodiments, advantages and the like, which are listed below for the purpose of avoiding repetition only as an aspect of the invention, of course also apply accordingly with respect to the other aspects of the invention, without this requiring a separate mention.

In the case of all relative or percentage weight-related data given below, in particular quantities, it is further to be noted that within the scope of the present invention, these are to be selected by the person skilled in the art in such a way that they include all components or ingredients in particular, as defined below always add or add up to 100% or 100% by weight; but this is self-evident to the person skilled in the art.

Furthermore, the person skilled in the art may deviate from the weight, quantity and range indicated below, depending on the application or the individual case, without departing from the scope of the present invention.

In addition, it is true that all of the values or parameter information or the like mentioned below can in principle be determined or determined using standardized or explicitly stated determination methods or otherwise with methods of determination or measurement known per se to the person skilled in the art.

Having said that, the present invention will now be explained in detail below.

• (a) mindestens einen gegenüber Erkältungskrankheiten und/oder Allergien wirksamen homöopathischen Wirkstoff ("Komponente (a)"); und
• (b) mindestens eine Schleimdroge, insbesondere in Form von deren Extrakt und/oder Bestandteil(en), und/oder mindestens einen Schleimstoff ("Komponente (b)");

enthält. The present invention - according to a first aspect of the present invention - is a composition, in particular a pharmaceutical composition, which is preferably suitable for use in the prophylactic and / or therapeutic treatment of respiratory diseases, especially colds and / or allergies, wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts

• (a) at least one homeopathic active substance effective against colds and / or allergies ("component (a)"); and
• (b) at least one mucilaginous drug, in particular in the form of its extract and / or constituent (s), and / or at least one mucilage ("component (b)");

contains.

Surprisingly, the Applicant has found in the context of the present invention that based on the combination of ingredients according to the invention, which comprises at least one active against colds or allergies homeopathic active ingredient on the one hand and at least one mucus drug or at least one mucilage on the other hand, compositions for the treatment of by most diverse Causes triggered respiratory diseases, especially colds or allergies, can be provided, which have over the prior art, an improved profile of action and, moreover, fewer side effects.

The present invention is associated with numerous advantages and particularities, which are discussed below in a non-limiting manner and are to be considered indicative of patentability.

On the basis of the composition according to the invention an effective agent for the treatment of respiratory diseases, especially colds and / or allergies, provided, which is free of drugs with strong side effects, such as vasoconstrictors, antihistamines, cortisone or anti-inflammatories, eg. Aspirin or paracetamol. The composition according to the invention thus has at least substantially no risk of, in particular, systemic side effects or incompatibilities, as often associated with the abovementioned active substances or active ingredient classes.

The homeopathic active ingredients used in the present invention show - especially in the context of the combination according to the invention with at least one mucilaginous or at least one mucilage - excellent efficacy in relation to the symptoms of respiratory diseases, such as (allergic or cold-induced) runny nose, cough, hoarseness and / or general allergic complaints. In particular, inflammatory conditions can also be treated effectively with the abovementioned active ingredient combination according to the invention.

In particular, the active ingredients used according to the invention, i. the at least one homeopathically active substance on the one hand and the at least one mucus drug or the at least one mucilage on the other hand, in a synergistic manner. Without wishing to be limited to this theory, the mucus drug or mucilages form a film-like, dense matrix on the mucosa, i. A protective protective layer is built up. The irritated and dry mucous membrane of the respiratory tract is rehydrated and regenerated on this basis so that the homeopathic active ingredients can develop their effect there with greater efficiency. The used homeopathic active ingredient is enhanced by the mucosal protection even further in its specific effect, so that the effect of the respective single active ingredients in combined use on the effect when administered alone significantly.

In addition, the compositions according to the invention have excellent wound healing properties. The active ingredient combination according to the invention leads to a rapid regeneration and a swelling of the irritated mucous membrane. In addition, the regenerating or regenerated mucosa is also protected on the basis of the formation of the protective film described above, in particular against the penetration of other pathogens, since the protective film has a certain barrier effect against these.

The compositions according to the invention also lead to an excellent alleviation of the respiratory symptoms accompanying pain symptoms. The associated with irritated mucosa pain in coughing, runny nose or hoarseness can be alleviated with the compositions of the invention.

Furthermore, the compositions according to the invention are extremely convenient to use and can be tailored to the dosage form, depending on the intended use. In particular, the compositions according to the invention may be lozenges or lozenges, solutions or juices or aerosols or sprays which are preferably to be administered nasally.

On the basis of an optional incorporation of further active substances or ingredients, the active profile and stability behavior of the composition according to the invention can be further controlled or specifically adjusted.

The compositions of the invention are also very variable in use and are suitable for the treatment of a variety of respiratory diseases. Both the typical symptoms associated with influenza infections and colds, such as sore throat, hoarseness, runny nose and cough, as well as the symptoms associated with allergies, especially allergic rhinitis, irritation of the mucous membranes and burning or watery eyes, can be at high efficacy at the same time low Treat side effects with the compositions of the invention successfully.

The term "pharmaceutical composition" or "pharmaceutical preparation", as used in the context of the present invention, is to be understood broadly and includes not only pharmaceutical preparations or pharmaceuticals and pharmaceuticals as such, but in particular also homeopathic remedies, so-called medical devices, foods or dietary supplements.

In the context of the present invention, respiratory diseases are understood to be, in particular, diseases affecting the respiratory tract or the respiratory tract. The respiratory tract comprises an upper portion including the nasal cavity, pharynx, and paranasal sinuses, and a lower portion comprising the larynx, trachea, and branch of the bronchial tree, including the lungs. In particular, the respiratory tract disorders to be treated with the composition according to the invention may be infectious respiratory diseases, ie infections caused by pathogens, in particular bacteria, viruses or fungi. These are preferably colds or flu infections, bronchitis, cough, runny nose and / or sinusitis. In addition, the term respiratory diseases in the context of the present invention also means allergic respiratory diseases or respiratory diseases caused by allergies and / or by contact with allergens, in particular allergic rhinitis or allergic rhinitis. Allergic rhinitis can be triggered in particular by various pollen, house dust and / or fungi as allergens.

In the context of the present invention, the term homeopathic active ingredient is understood as meaning active ingredients which are obtained by means of recognized homeopathic preparation methods. These are, in particular, the mother tinctures obtained from vegetable basic substances. In the context of the present invention, the term "mother tinctures" refers to the concentrated, liquid preparation of a vegetable press juice preferably mixed with ethanol or a plant extract and / or plant extract. The homeopathic active ingredient may also be present as a diluted, in particular potentiated, solution based on the respective mother tincture.

As regards the slime drugs used in the context of the present invention, these are in particular drugs derived from fungi, plants, animals or microorganisms which contain water-binding biopolymers, in particular polysaccharides, as ingredients. In the context of the present invention, the biopolymers or polysaccharides are usually heteropolysaccharides with molecular weights of about 50,000 to 2,000,000, which are obtained by extraction with hot or cold water from the drug. The high-viscosity solutions are not tacky in contrast to the gums. In addition, a distinction can be made between acidic and neutral slime. Depending on their sugar composition, they can be divided into glucomannans or mannans, galactomannans, xylans or rhamnogalacturonans. After their localization in the plant, one can distinguish vacuolar mucus and membrane mucus. The mucus of the marshmallow root can be regarded as a prototype for an acid mucus. It contains L-rhamnose, D-galactose, D-galacturonic acid and D-glucuronic acid in a molecular ratio of approximately 3: 2: 3: 3. The simplest built part of the polysaccharide consists of repeating undecasaccharide subunits.

In the context of the present invention, it has proven to be particularly effective in the field of using mucous drugs based on marshmallow, mallow or Icelandic moss.

By contrast, the term "mucilages", as used in the context of the present invention, is understood in particular to mean macromolecular carbohydrates whose molecules consist of a number of at least> 10 glycosidically linked monosaccharide molecules. The mucilage includes numerous biopolymers or polymers of biogenic origin, which can have extremely variable chemical or pharmacological properties. Polysaccharides are mainly used as reserve substances and are usually present as homopolymers or homoglycans, which are each based on one type of monosaccharide. In addition, there are mucilages which can bind large amounts of water with gelation. For the composition according to the invention, the use of mucilage has proven to be particularly advantageous because they show a particularly strong affinity for the oral, nasal or pharyngeal mucosa and form a protective film, so to speak, which protects the mucous membrane against the entry of pathogens such as cold viruses , and on the other hand prevents fluid loss or the symptoms of dry mouth.

As already mentioned above, the active ingredients or active components used in the compositions according to the invention complement each other synergistically. The mucus drugs or mucilages used form a kind of protective matrix on the irritated and damaged mucous membrane, which in particular also prevents further drying out. Due to the formation of the protective film, in particular by increasing the moisture and preventing further drying of the mucous membranes, the homeopathic agents used can reach the site of action with greater efficiency of action and unfold their effect there. On this basis, both a rapid onset of action as well as an excellent efficiency and a long-lasting duration of action are guaranteed.

The present invention may be configured in a variety of ways. Preferred embodiments are described in detail below.

As far as the selection of the at least one homeopathic active ingredient is concerned, particularly good results are achieved in the context of the present invention if the homeopathic active ingredient and / or component (a) is at least one ingredient isolated and / or extracted from plants.

It may be provided in particular that the plants are selected from the group of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galphimia glauca. Likewise, it can be provided that the homeopathic active ingredient and / or the component (a) is at least one plant-derived extract or its component. The plants may be selected in particular from the group of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galphimia glauca.

The plants of the genus Drosera are different species or species of the sundew. Drosera rotundifolia, Drosera intermedia and / or Drosera anglica have proven to be particularly effective for the use according to the invention. The sundew is known as a carnivorous plant and occurs mainly in Asian and North American, but partly also in European peat bogs. The homeopathic active ingredients of sundew are produced in particular from the flowers of the plants. The extraction of the active ingredients or the preparation of the mother tincture can be carried out in particular in accordance with regulation 1.1.3 of the prescription collection 2371 of the Ph. Eur. (See also V 2a Homeopathic Pharmacopoeia (HAB)) with ethanol.

In the context of the present invention, it has surprisingly been found that homeopathic active substances from Drosera rotundifolia, Drosera intermedia and / or Drosera anglica have excellent activity in the treatment of symptoms of respiratory diseases, in particular pain, in particular when combined with at least one mucous drug or at least one mucilage , Hoarseness and coughing, own. In particular, the homeopathic agents are characterized by their excellent anti-inflammatory effect in the context of the treatment of respiratory diseases, which can be completely further enhanced by the additional use of mucus drugs or mucus substances even further.

The plant Arum triphyllum, synonymous also Arisaema triphyllum or three-leaved Aaronstab or Zehrwurzel, is a poisonous plant, which is native to America and China. Aaronstab contains large amounts of oxalate, volatile pungent, the bitter saponin Aroin and the alkaloid Coniin, which can lead to severe poisoning even in small amounts on contact with or consumption of plant parts. Only by boiling or drying the Aaronstab loses its toxicity. The extraction of the active ingredients or the preparation of the mother tincture can in particular according to regulation 1.1.5 of the set of rules 2371 of the Ph.Eur. (V 3a HAB) with ethanol. To provide the mother tincture, in particular the tuber or root of the plant can be used.

In the context of the present invention, it has surprisingly been found that the homeopathic active substances from Arum triphyllum, in particular in combination with the other active components used according to the invention, have outstanding properties with regard to alleviating inflammatory symptoms on the respiratory tract, in particular the upper respiratory tract. In particular, the active ingredients from the zehoot root also lead to a significant alleviation of pain associated with respiratory diseases pain.

Galphimia glauca is also a poisonous plant, which is synonymously or in German also referred to as small laburnum and as a shrub growing mainly in Central America and Mexico. For the production of the mother tincture for homeopathic active ingredients from Galphimia glauca, in particular the dried leaves and inflorescences are used. The mother tincture can be prepared in particular according to the Homeopathic Pharmacopoeia (HAB 2000).

In the context of the present invention, homeopathic active substances based on Galphimia glauca have an outstanding effectiveness, in particular in the treatment of allergic complaints, sneezing, stuffy nose and intense itching on the palate, in the throat or throat and on the nasal mucosa. In addition, a dryness of the mucous membranes can be significantly alleviated.

The aforementioned homeopathic active ingredients can be obtained or provided in particular by the provision of so-called mother tinctures. As mentioned above, mother tinctures are in particular concentrated, liquid preparations which are obtained by pressing out plant components and then mixing the resulting compressed juice with solvents, in particular ethanol, or by extracting or extracting the plant components with suitable extraction agents, such as ethanol , As starting materials, both fresh and dried components of the aforementioned plants can be used. In addition, the plant components may be subjected to maceration, heat treatment, decoction or fermentation before being pressed out or before extraction. The provided mother tinctures can be further mixed or diluted, which is also called potentizing. The provision of the mother tinctures can be done in particular according to recognized homeopathic practice, as described in particular in the Homeopathic Pharmacopoeia or in the European Pharmacopoeia.

In the context of the present invention, it can be provided in particular that the component (a) and / or the homeopathic active ingredient by aqueous, aqueous-alcoholic or alcoholic extraction of plant components, especially the plants Drosera, especially Drosera rotundifolia, Dosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galvinia glauca, to obtain a mother tincture.

Furthermore, it has been found in the context of the present invention to be particularly advantageous when the mother tinctures are used according to the usual homeopathic practice in diluted form, the dilution is done in particular by potentiating.

In the course of potentiation, in the context of the present invention, the previously obtained mother tincture is gradually shaken with water and / or alcohol to provide it with respect to the mother tincture of low-concentrated solutions of the homeopathic active ingredients, or alternatively triturated with milk sugar. According to the invention, it is preferable to further dilute the mother tinctures by means of shaking. It is based on the mother tincture, which initially in the ratio of 1:10, d. H. one part of mother tincture and 9 parts of solvent, 1: 100 (one part of mother tincture, 99 parts of solvent) or 1: 50,000 (one part of mother tincture, 49.999 parts of solvent) diluted with a solvent and then shaken with a specified number of strokes. The combination of dilution and shaking is carried out in each potentiating step. When potentiating, in principle, in decimal potencies (D-potencies), which provide a dilution of 1:10 and 10 shakes per dilution or potentiation step, centipale potencies (C potencies, dilution 1: 100 per step and 10 shakes) or Quinquaginta-Millesimal Potencies (Q potencies, dilution 1: 50,000 with 100 shakes and use of an additional carrier substance) are assumed. In view of the effectiveness of the at least one homeopathic active ingredient in the compositions according to the invention, it has proved to be particularly advantageous to use the mother tinctures in D-potencies, i. in dilution steps of 1:10, to dilute.

In the context of the present invention, it can therefore be provided in particular that the homeopathic active ingredient and / or component (a) have a decimal potency in the range from D1 to D30, in particular in the range from D2 to D15, preferably in the range from D3 to D10, is preferably used in the range of D4 to D7, based on the mother tincture of the homeopathic active ingredient.

As far as the amounts of the at least one homeopathic active substance used are concerned, it has proved to be particularly advantageous if the composition according to the invention comprises the homeopathic active ingredient and / or component (a) in an amount in the range from 0.00001 to 10% by weight. , in particular in the range of 0.0001 to 5 wt .-%, preferably in the range of 0.0005 to 4 wt .-%, preferably in the range of 0.0009 to 3 wt .-%, based on the composition.

With respect to component (b), it is also provided in the context of the present invention that it is selected from at least one mucilage and / or at least one mucus drug. In other words, component (b) can be formed either by at least one mucus drug, by at least one mucilage or by a combination of mucous drug (s) and mucilage (s).

As regards the specific choice of mucous drugs, particularly good results are obtained when the at least one mucilaginous drug is selected from the group of Icelandic moss (Lichen islandicus), marshmallow (Althaea officinalis L.), plantain (Plantago lanceolata L.), mallow ( Malva sylvestris L. and M. neglecta WALLR.), Fenugreek (Trigonella foenum-graecum L.), salep and / or quince (Cydonia oblonga MILL.), And combinations and mixtures thereof. According to a particularly preferred embodiment the at least one mucilaginous drug may in particular be selected from the group of Icelandic moss (Lichen islandicus), marshmallow (Althaea officinalis L.) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.) and combinations thereof.

Icelandic moss is the German name for Lichen islandicus or Cetraria islandica (Parmeliaceae), ie a lichen (ie not a moss contrary to the German name), which is exported from northern countries, such as Iceland, Norway and Sweden. Icelandic moss in the true sense consists in particular of the dried thallus of Cetraria islandica and its preparations. The drug contains, among other things, mucilage and bitter substances as well as bitter tasting lichen acids. About 60 wt .-% dissolve from the powdered lichen on boiling with highly dilute sodium bicarbonate solution, and upon cooling of the solution, a jelly. The extract consists of a polysaccharide mixture of lichenin and isolichenin, a series of bitter-tasting lichen acids (fumarprotocetrar, protocetraric and cetraric acid) and protolichesteric acid, which converts to lichesteric acid during work-up, and usnic acid as an antibiotic lichen dye. As a mucus drug Icelandic moss has soothing properties, it also has an antimicrobial effect. The Bitterstoffgehalt justified its use in loss of appetite. Icelandic moss is used for example in catarrh and diarrhea, as bitter tonic, externally in poorly healing wounds, in cosmetic preparations, in loss of appetite and in irritation of the mucous membranes in the mouth and throat. An oral and Rachendesinfiziens based on Icelandic moss has a soothing effect on dry irritated cough. The cold macerate and other bitter-tasting preparations of the drug are used to remedy the sub- or antacidity. As dosage forms, depending on the field of application, the comminuted drug for infusions and other galenic preparations or the comminuted drug are preferably used for cold macerates and other bitter-tasting preparations for oral use. For further details on Icelandic moss, for example, reference may be made to the following references: Römpp Chemie-Lexikon, 9th edition, Volume 3, Georg Thieme Verlag, Stuttgart / New York, 1990, pages 2055/2056, keyword: "Icelandic moss" ; HagerROM 2001, Springer Verlag, Heidelberg, keywords: "Cetraria", "Cetraria ericetorum OPIZ", "Cetraria islandica (L.) ACHARIUS" and "Lichen islandicus (Icelandic moss)" ; Monograph "Lichen islandicus (Icelandic moss)", Federal Gazette No. 43 of 2 March 1989 ; H. Wagner, "Pharmaceutical Biology - Drugs and their Ingredients", Gustav Fischer Verlag, Stuttgart / New York, 1985, page 281, keyword: "Cetrariae Lichen (= Lichen islandicus - Icelandic moss)" ,

The marshmallow (Althaea officinalis L.), especially used in the form of the marshmallow root, leaves and flowers, grows on saline and moist soils of Central, Eastern and Southeastern Europe. The root branches and secondary roots harvested in the autumn, freed from the main woody root, rootlets and bark layers and dried at 35 ° C, come on the market either peeled or unpeeled. The brown color of the peeled drug means a reduction in quality; a subsequent "beauty" with sulfite solution is inadmissible. Also used are the approximately 10 cm long, about 8 cm wide, three- to five-lobed, gray-haired, hairy dried leaves collected before or during flowering and the flesh-colored dried petals collected in July / August. The marshmallow is a perennial, about 1 m high perennial, which is propagated generatively or vegetatively. The root harvested in late autumn contains up to 15% mucilage. In the spring and summer, the mucus content is 5 to 6%. The mucus content of the leaf and flower drug is 6 to 9%. The mucus is localized in the root in certain mucous cells of the bark and wood parenchyma. It consists of galacturonorhamnanes, glucans and arabinogalactans. Aqueous extracts from the root should be prepared by maceration at room temperature so that the abundant starch does not interfere with swelling. Marshmallow drugs are used for tea preparations or for making Sirupus Althaeae. The main application area is inflammatory irritation of the pharynx. Externally, the marshmallow is used for softening envelopes, baths and cataplasms.

The ribwort plantain (Plantago lanceolata L.) is found throughout Europe as well as in northern and central Asia. The drug comes from wild plants and cultures, especially in southeastern Europe. The dried, olive to brownish green colored, lanceolate leaf blades with about three to seven parallel nerves can be used. The herba drug consists of the dried leaves, stems and whole flowers. In addition to the mucus, ribwort contains further tannins, the iridoid glycoside aucubin (1.9 to 2.4%), which is responsible for the darkening of a drug that has not been carefully dried and is used for identity verification, and the mustard oil sulforaphane. The ribwort plantain, in particular the plantain leaf herb, finds particular application in the form of teas and syrups in inflammation of the mouth and throat.

The mallow (Malva sylvestris L. and M. neglecta WALLR.), Especially in the form of mallow flowers and leaves, is native to Europe, Asia Minor, the Mediterranean and the Near East. to Use comes at the time of flowering collected, pink-violet colored flowers or strongly shrunk by drying, folded leaves that come mostly in package form on the market. The mallow is a herb of two to several years. The mucus content of flowers and leaves is 6 to 8%. In the hydrolysis, the mucus provides glucose, arabinose, rhamnose and galactose. Mallow flowers are used for gurgling waters and baths and along with the leaves in tea blends as expectorans.

The fenugreek (Trigonella foenum-graecum L.), especially used in the form of the fenugreek seed, is found throughout the Mediterranean, as well as in Eastern Europe, India and China. The main drug import comes from the cultures of India and Morocco. Used are the brown-reddish, four-sided and diamond-shaped, about 5 mm long and about 3 mm wide, flattened, very hard seeds that are characterized by a furrow. The drug contains 20-30% mucus, trigonellin, nicotinic acid amide, choline, bittering agents and saponins in addition to fatty oil. The production of the mucus takes place from the powdered seed. The powder is used externally to envelopes in boils, ulcers and glandular swelling, internally as an expectorant and Roborans.

Salep or Salep Tuber, especially used in the form of the Salep tuber, is derived from various species of orchids, especially Orchis mascula L., Orchis morio L., Orchis militaris L., Anacamptis pyramidalis L. RICH. and Platanthera bifolia L. RICH. Used are the about 4 cm long to about 3 cm thick, wrinkled, hard, brownish tubers, which are freed from the basket layer after harvesting, brewed with boiling water and dried with artificial heat. Salepschleim, which consists up to 50% predominantly of glucomannan or glucan, is mainly used in children's nursing practice as antidiarrhoeal.

The quince (Cydonia oblonga MILL.) Is native to southeastern Arabia. Skin drug imports come from Spain, Portugal and Persia. The mature, dried, red-brown to brown-purple colored, slightly flattened seeds of the quince fruit are used. The seeds are on the outside partially provided with a dried-up mucus crust and often glued together. They have a weak bitter almond taste. In the epidermis is found about 22% mucus, which is largely soluble in water. The sugar components are arabinose, xylose and uronic acid, which is partially methylated. The drug is used only uncrushed. The quince mucus is used externally in lip and nipple humors, in burns and bedsores in ointment or cream form.

According to a particularly preferred embodiment, the mucus drug may preferably be Marshmallow (Althaea officinalis L.) and / or Icelandic moss (Lichen islandicus) and / or Mallow (Malva sylvestris L. and M. neglecta WALLR.).

As far as the slime drugs used are concerned, it may in particular be provided that the at least one slime drug is used in the form of an extract, in particular a liquid extract and / or fluid extract. In this context, it may be provided in particular that the at least one mucilaginous drug is used in the form of an aqueous, alcoholic or aqueous-alcoholic extract, in particular an alcoholic or aqueous-alcoholic extract.

The effectiveness of the composition according to the invention can be further increased even further, if the at least one mucilaginous drug in the form of an extract, in particular liquid extract, with a drug / extract ratio of at least 0.5: 1, in particular at least 0.6: 1, preferably at least 0.8: 1, more preferably at least 0.9: 1 or more is used.

In this connection, it may in particular be provided that the at least one mucous drug in the form of an extract, in particular liquid extract, with a drug / extract ratio in the range from 0.4: 1 to 15: 1, in particular in the range of 0.5: 1 to 10: 1, preferably in the range from 0.6: 1 to 8: 1, particularly preferably in the range from 0.8: 1 to 5: 1, very particularly preferably in the range from 0.9: 1 to 3: 1 , more preferably about 1: 1, is used.

The so-called drug / extract ratio (DEV) characterizes the (weight-related) ratio of starting drug used to extract obtained. The drug / extract ratio (DEV) thus indicates from which weight-related amount of drug used (eg lichen islandicus) which weight-related amount of extract has been obtained. A drug / extract ratio, for example, of 10: 1 means that one part by weight of extract was obtained from ten parts by weight of the drug. The drug / extract ratio thus indicates how many parts by weight of a drug drug are required for the preparation of the weight-related extract equivalent.

The use of extracts with defined drug / extract ratio is particularly relevant in the light of the fact that the quality of the extract has a decisive influence on the overall quality of the pharmaceutical composition. The aim is also to standardize the extract in terms of drug concentration, so that the final pharmaceutical preparation can be provided qualitatively and quantitatively with consistently good levels of active ingredients and ingredients.

As far as the at least one mucilage is concerned, it has proved to be particularly advantageous if it is selected from the group of carrageenans and / or their physiologically tolerated salts, hyaluronic acid and / or their physiologically acceptable salts (eg alkali hyururonates) and / or Xanthanes and / or their physiologically acceptable salts.

The hyaluronic acid or its salts, in particular sodium hyaluronate, used according to the invention are acidic glycosaminoglycans in the form of linear mucopolysaccharides, which are formed from repeating saccharides. Chemically, hyaluronic acid is a macromolecular chain of disaccharides based on D-glucuronic acid and N-acetyl-D-glucosamine linked by a beta-1,3-glucosidic linkage. In turn, the disaccharides are linked together via a beta-1,4-glucosidic bond to a polymeric chain. In general, a hyaluronic acid polymer consists of 250 to 50,000 disaccharide units.

Hyaluronic acid is an important component of connective tissue in the human or animal body and also plays a role in cell proliferation and cell migration. In the context of the present invention, in particular the cell proliferative effect with respect to a rapid regeneration of the tissue has proved to be advantageous. Furthermore, hyaluronic acid has the ability to bind extremely large amounts of water: Thus, with 1 g of hyaluronic acid up to 6 liters of water can be bound. By binding large amounts of water, dehydration of the skin or mucous membrane can be prevented in an efficient manner, so that accelerated regeneration of the tissue is made possible and the skin or mucous membrane also remains elastic.

In the context of the present invention, the term "carrageenan" or "carrageenan" is understood to mean a collective name for a group of long-chain polysaccharides which occur or are synthesized in particular in cells of different types of red algae. Carrageenans are linear anionic hydrocolloids, with different types of carrageenan depending on the chemical structure. Due to the particular structure, different properties also result for the different types. The assignment is based primarily on the proportion of galactose and 3,6-anhydrogalactose and the number of sulfate groups. To produce carrageenan from red algae these are first washed and boiled in alkaline solution. Subsequently, the solution is filtered to separate the cell debris from the polymer. To obtain the carrageenan from the solution, the carrageenan is finally either precipitated by means of alcohol or gelled by means of potassium chloride and then pressed off. The recovered carrageenan can then be dried, ground and further processed depending on the application. Of particular commercial interest are, in particular, kappa, iota and lambda carrageenan. Nevertheless, other types of carrageenan can alternatively be used, which then serve in particular as precursors for kappa, iota and lambda carrageenan.

In the context of the present invention, it can be provided, in particular, that the at least one mucilage is selected from the group of carrageenans, especially alpha, iota, gamma, kappa and / or lambda carrageenan and / or physiologically acceptable salts.

In addition, the term "xanthan" in the context of the present invention, a natural polysaccharide understood, which contains as monomers, in particular glucose, glucuronic acid, mannose and, moreover, pyruvic acid. The backbone of the xanthan polymer is formed in particular by beta-1,4-linked D-glucose units. In addition, every other unit of glucose via alpha-1,3-glycosidic linkages is a beta-D-mannopyranosyl- (1,4) -beta-D-glucuronapyranosyl- (1,2) -6-O-acetyl-alpha-D -mannopyranosyl side chain knotted. Furthermore, about half of the terminal mannose units of the side chain form a ketal with pyruvic acid via the free hydroxyl groups at positions 4 and 6. In addition, it is possible that the acetyl group or a side chain is completely absent.

Usually, xanthan gum is obtained by means of microorganisms of the genus Xanthomonas, starting from sugary substrates, and used industrially as a thickener or gelling agent. In addition, xanthan has water-binding properties and swells in aqueous solution, so that the viscosity of the medium is increased. Also xanthanum bends in the context of the use of the invention Drying out of the mucous membranes before or leads to a relief of dried out mucous membrane. Xanthan gum also enhances the formation of a protective film on the mucosa.

The amount of mucous or mucilage or component (b) used can vary within wide limits. Particularly good results are achieved if the composition according to the invention comprises the at least one mucous drug and / or the at least one mucilage and / or component (b) in an amount in the range of 0.00001 to 30 wt .-%, in particular in the range of 0 , 0001 to 20 wt .-%, preferably in the range of 0.005 to 15 wt .-%, preferably in the range of 0.001 to 10 wt .-%, based on the composition.

In the context of the present invention, as component (b), the abovementioned mucilages and / or mucous drugs can each be used individually or in combinations.

In addition, it can be provided in the context of the present invention that the composition at least one other active ingredient and / or ingredient, in particular selected from the group of (mucus) skin protection agents, antiseptics, local anesthetics, vitamins, trace elements, minerals, micronutrients and their Combinations, contains.

Likewise, it may be provided that the composition contains at least one customary pharmaceutical additive and / or adjuvant, in particular selected from the group of processing aids, stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH adjusters, pH buffer substances, thickeners, flavorings , Antiseptics, coloring, buffering, scent, fragrance, extender, binding, wetting and / or preservatives and their combinations.

According to a particularly preferred embodiment of the present invention, it may be provided that the composition is present as a solid dosage form or that the composition is present as a tablet, dragee, pill, hard caramel or the like. In the context of the present invention, it is particularly preferred if the composition according to this preferred embodiment is present as a lozenge. It may be provided in particular that the solid dosage form, in particular the lozenge, a total weight in the range of 0.5 to 7 g, in particular in the range of 1 to 6 g, preferably in the range of 2 to 5 g.

In particular, with respect to the compositions of the invention in the form of solid dosage forms, it may be contemplated that the solid dosage form is formed such that the solid dosage form releases a therapeutically effective amount of the active ingredients and / or ingredients in sucking when the solid dosage form is in the mouth and throat of a patient is administered and sucked.

As far as the composition according to the invention is concerned in the form of a solid dosage form, it has proven to be advantageous in this context if it contains the active substances and / or ingredients in a solid matrix and / or mass, in particular in a matrix and / or mass Base of sugars and / or sugar substitutes. Sugars which may be selected from the group of sucrose, glucose, in particular dextrose, and fructose have proved particularly suitable in this connection. Furthermore, as regards sugar substitutes as a solid matrix or mass, these may be selected in particular from sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructooligosaccharides, glucans, polyglucose, more preferably isomalt and / or mannitol.

As far as the amount of sugars or sugar substitutes used is concerned, this can vary widely. Particularly good results are achieved when the solid dosage form contains sugar and / or sugar substitutes in a relative amount in the range of 20 to 99% by weight, in particular in the range of 30 to 90% by weight, preferably in the range of 35 to 85% by weight .-%, preferably in the range of 40 to 80 wt .-%, based on the composition contains.

In order to enable a good efficacy of the composition according to the invention in the form of a solid dosage form, it has moreover proved advantageous if the solid dosage form contains the at least one homeopathic active ingredient and / or component (a) in an amount in the range of 0.000001 to 1 wt .-%, in particular in the range of 0.00001 to 0.5 wt .-%, preferably in the range of 0.0001 to 0.1 wt .-%, preferably in the range of 0.0005 to 0.01 Wt .-%, particularly preferably in the range of 0.0009 to 0.005 wt .-%, based on the composition contains.

With regard to the selection of the at least one homeopathic active substance for a solid dosage form, it may be provided, in particular, that the at least one homeopathic active ingredient and / or component (a) is an ingredient isolated and / or extracted from Arum triphyllum or that the homeopathic active ingredient and / or component (a) is at least one extract derived from Arum triphyllum or its component.

In the context of the present invention, it has surprisingly been found that a solid dosage form which contains Arum triphyllum as a homeopathic active ingredient leads to an excellent alleviation of complaints associated with respiratory diseases, in particular colds. In particular, acute inflammation of the upper airways and inflammation of the oral cavity and salivary glands can be treated with excellent efficacy. Also, a dehydration of the mucous membranes can be alleviated or dehydration prevented, so that in particular the symptom of hoarseness and / or dry mouth can be counteracted with high efficiency. By incorporating the active ingredient in a solid dosage form, the efficiency of action as well as the duration of action can be increased because the active ingredients are released over a long period of time when sucking the solid dosage form.

Moreover, as regards the amount of component (b) used in the compositions of the invention in the form of solid dosage forms, it has proved to be particularly advantageous if the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range of 0.001 to 10 wt .-%, in particular in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2 wt .-%, preferably in the range of 0.1 to 1 wt .-%, particularly preferably in the range of 0.2 to 0.8 wt .-%, based on the composition contains.

In this context, the amount of component (b) refers to the total amount of mucilages and / or mucous drugs used in their entirety.

According to a preferred embodiment it can be provided that the solid dosage form contains as component (b) at least one mucilage, in particular wherein the at least one mucilage is selected from hyaluronic acid and / or their physiologically acceptable salts and / or carrageenans and / or their physiologically acceptable Salt.

In the context of the present invention, it has surprisingly been found that the additional use of at least one mucilage, in particular in the form of hyaluronic acid and / or carrageenans, further increases the effective efficiency of the compositions according to the invention in solid dosage form in the treatment of respiratory diseases, in particular colds leaves. In particular, the additional use of at least one mucilage, in particular hyaluronic acid and / or carrageenans, leads to a further improved wetting of the upper respiratory tract mucosa, in particular of the pharynx or neck. In addition, pain conditions are further alleviated by the additional use of hyaluronic acid. In addition, hyaluronic acid and / or carrageenans form a protective film on the mucous membrane, which protects against the penetration of other pathogens and / or allergens.

According to a preferred embodiment of the present invention, it can thus be provided in particular that the solid dosage form contains as component (b) a combination of hyaluronic acid and / or its physiologically acceptable salts and at least one carrageenan and / or its physiologically acceptable salts.

In particular, it may be provided in this context that the solid dosage form hyaluronic acid and / or their physiologically acceptable salts in an amount in the range of 0.00001 to 5 wt .-%, in particular in the range of 0.0001 to 1 wt .-% , preferably in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, particularly preferably in the range of 0.01 to 0.05 wt .-%, based on the composition , contains.

Moreover, it is inventively preferred if the solid dosage form at least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 20 wt .-%, in particular in the range of 0.001 to 10 wt .-%, preferably in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2 wt .-%, particularly preferably in the range of 0.1 to 1 wt .-%, based on the composition.

• (a) mindestens einen aus Arum triphyllum isolierten und/oder extrahierten Inhaltsstoff und/oder mindestens einen aus Arum triphyllum gewonnenen Extrakt oder dessen Bestandteil in einer Menge im Bereich von 0,00001 bis 1 Gew.-%, insbesondere im Bereich von 0,00005 bis 0,5 Gew.-%, vorzugsweise im Bereich von 0,0001 bis 0,1 Gew.-%, bevorzugt im Bereich von 0,0005 bis 0,01 Gew.-%, besonders bevorzugt im Bereich von 0,0009 bis 0,005 Gew.-%, bezogen auf die Zusammensetzung; und
• (b) Hyaluronsäure und/oder deren physiologisch verträgliche Salze in einer Menge im Bereich von 0,00001 bis 5 Gew.-%, insbesondere im Bereich von 0,0001 bis 1 Gew.-%, vorzugsweise im Bereich von 0,001 bis 0,5 Gew.-%, bevorzugt im Bereich von 0,005 bis 0,1 Gew.-%, besonders bevorzugt im Bereich von 0,01 bis 0,05 Gew.-%, bezogen auf die Zusammensetzung, und mindestens ein Carrageen und/oder dessen physiologisch verträgliche Salze in einer Menge im Bereich von 0,0001 bis 20 Gew.-%, insbesondere im Bereich von 0,001 bis 10 Gew.-%, vorzugsweise im Bereich von 0,01 bis 5 Gew.-%, bevorzugt im Bereich von 0,05 bis 2 Gew.-%, besonders bevorzugt im Bereich von 0,1 bis 1 Gew.-%, bezogen auf die Zusammensetzung;

enthält. The present invention according to a preferred embodiment of the composition according to the invention is thus a composition as described above, in the form of a solid dosage form, wherein the solid dosage form in combination and in each case in effective, in particular pharmaceutically effective amounts

• (a) at least one ingredient isolated from Arum triphyllum and / or extracted and / or at least one extract obtained from Arum triphyllum or its constituent in an amount in the range of 0.00001 to 1% by weight, in particular in the range of 0.00005 to 0.5 wt .-%, preferably in the range of 0.0001 to 0.1 wt .-%, preferably in the range of 0.0005 to 0.01 wt .-%, particularly preferably in the range of 0.0009 to 0.005 wt .-%, based on the composition; and
• (b) hyaluronic acid and / or physiologically acceptable salts thereof in an amount in the range of 0.00001 to 5% by weight, in particular in the range of 0.0001 to 1% by weight, preferably in the range of 0.001 to 0.5 Wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, particularly preferably in the range of 0.01 to 0.05 wt .-%, based on the composition, and at least one carrageenan and / or its physiological acceptable salts in an amount in the range of 0.0001 to 20 wt .-%, in particular in the range of 0.001 to 10 wt .-%, preferably in the range of 0.01 to 5 wt .-%, preferably in the range of 0, From 05 to 2% by weight, particularly preferably in the range from 0.1 to 1% by weight, based on the composition;

contains.

According to a further and invention equally preferred embodiment of the present invention, it may also be provided that the solid dosage form is formed as a multi-phase system with at least two different phases. In this context, it can be provided, in particular, that the solid dosage form has an outer phase, in particular a capsule shell, and an inner phase, in particular a capsule core.

On the basis of the provision of the solid dosage form as a multiphase system, a targeted or time-delayed release of the active ingredients or ingredients can be ensured. It may be provided in particular that after ingestion of the dosage form as a multiphase system, first the active ingredients contained in the outer phase, in particular the capsule shell, are released. Later, or delayed, the release of the active ingredients or ingredients, which are in the inner phase, in particular capsule core, then takes place.

In this way, a particularly long-lasting duration of action can be achieved. In addition, the release of the active ingredients can be adjusted in a targeted manner or the release can be controlled in such a way that the active ingredients complement each other optimally in relation to their profile of action or unfold their effect successively and in addition to one another.

With regard to the release of the active ingredients from the multiphase system, it has proven to be advantageous on the whole if the solid dosage form in the form of a multiphase system has a capsule shell on the one hand and a capsule core on the other hand, d. H. the solid dosage form is constructed according to a "core / shell principle", so that not all phases are freely accessible after application of the capsule system for body fluids, in particular saliva and / or gastric acid, and a sustained release, in particular of the active ingredients contained in the capsule core, is made possible ,

In this context, it has proven to be particularly advantageous in terms of the profile of action, if initially starting from the capsule shell at least one mucus drug or at least one mucilage released and its effect unfolds, in particular forms a rehydrating protective film on the mucosa. Subsequently, the sustained release of at least one homeopathic or a homeopathic active ingredient, preferably in combination with at least one mucus drug, starting from the capsule core, whereby the homoeopathic active ingredient is further increased in its effectiveness by the previous training of the protective film.

As regards the design of the solid dosage form in the form of a multiphase system in particular, it has proved to be advantageous if the solid dosage form comprises the outer phase, in particular the capsule shell, in an amount in the range from 30 to 99% by weight, in particular Range of 40 to 98 wt .-%, preferably in the range of 50 to 96 wt .-%, preferably in the range of 60 to 95 wt .-%, particularly preferably in the range of 70 to 92 wt .-%, even more preferably in the range of 80 to 90% by weight, based on the composition.

Furthermore, it may be provided in this context that the solid dosage form the inner phase, in particular the capsule core, in an amount in the range of 1 to 70 wt .-%, in particular in the range of 2 to 50 wt .-%, preferably in the range 3 to 40 wt .-%, preferably in the range of 5 to 30 wt .-%, more preferably in the range of 7 to 20 wt .-%, even more preferably in the range of 8 to 15 wt .-%, based on the Composition comprising.

With regard to the active profile or the effective efficiency, it may also be provided that the solid dosage form contains the homeopathic active ingredient and / or the component (a) in the outer phase and / or in the inner phase, in particular in the inner phase, preferably in the Capsule core, contains.

As regards the amount of the at least one homeopathic active ingredient or component (a) used, a particularly good effect is achieved if the solid dosage form contains the at least one homeopathic active ingredient and / or component (a) in an amount in the range of 0 , 0001 to 5 wt .-%, in particular in the range of 0.001 to 3 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-% , based on the composition contains. According to a preferred embodiment, the solid dosage form contains the at least one homeopathic active ingredient and / or the component (a) - as mentioned above - preferably in the inner phase, in particular the capsule core.

As far as the selection of component (a) or of the homeopathic active substance is concerned, it is preferred according to the invention if this or these is at least one ingredient isolated from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica , Likewise, it may be provided in this context that the homeopathic active ingredient and / or component (a) is at least one extract or component thereof derived from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica.

In the context of the present invention, it has surprisingly been found that a homeopathic active ingredient based on sundew or species of the genus Drosera, in particular in multiphase systems with sustained release, has an excellent profile of action in the treatment of respiratory diseases, in particular the symptoms of colds. In particular in combination with at least one mucilaginous drug or at least one mucilage with time-delayed release, the homeopathic active ingredient leads to a relief of coughing and hoarseness. In addition, the symptoms associated with colds pain is alleviated.

As regards the further embodiment of this embodiment of the invention, it may be provided that the solid dosage form component (b) in the outer phase and / or in the inner phase, preferably in the outer phase, in particular the capsule shell, and in the inner Phase, in particular the capsule core contains.

Furthermore, it can be provided that the solid dosage form contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range from 0.001 to 20% by weight, in particular in the range from 0.01 to 15 wt .-%, preferably in the range of 0.1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, particularly preferably in the range of 1 to 2 wt .-%, based on the Composition containing.

In this connection, it has proved to be particularly advantageous if the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucous substance in the outer phase, in particular the capsule shell, in an amount in the range of 0.001 to 10 wt .-%, in particular in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2.5 wt .-%, preferably in the range of 0.1 to 1.5 wt. -%, based on the composition contains.

Equally, it can also be provided that the solid dosage form contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in the inner phase, in particular the capsule core, in an amount in the range from 0.0001 to 1 Wt .-%, in particular in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, preferably in the range of 0.01 to 0.09 wt .-%, based on the composition, contains.

By using component (b) in the abovementioned amounts both in the capsule shell and in the capsule core, an excellent efficiency of action of the composition according to the invention in the treatment of respiratory diseases, in particular colds, is achieved. In addition, also the retarded released homeopathic active ingredient, in particular based on Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, reinforced in its action.

According to a particularly preferred embodiment, it may be provided that the solid dosage form in the outer phase, in particular the capsule shell, as component (b) contains a combination of at least one mucous drug and at least one mucilage, in particular wherein the mucus drug Marshmallow (Althaea officinalis L.) and the mucilage is at least one carrageenan and / or its physiologically acceptable salts.

Furthermore, it can also be provided that the solid dosage form in the inner phase, in particular the capsule core, as component (b) contains at least one mucilage, in particular wherein the mucilage is at least one carrageenan and / or its physiologically acceptable salts.

On the basis of the use of the mucilage or mucus drug both in the outer phase and in the inner phase, a longer duration of action is achieved in addition to the improved efficacy, since the mucous membranes of the upper airways constantly over a longer period with the mucus drug or the mucilage in Contact come and be wet. On this basis, without wishing to be limited to this theory, a protective film forms on the mucous membrane, which on the one hand leads to wetting or rehydration of the irritated mucous membranes and, moreover, a barrier effect against other pathogens, such as bacteria or viruses , represents.

Furthermore, as far as the amounts of the selected slime drugs or mucilages used are concerned in detail, they can vary within wide ranges.

In order to ensure a good efficiency of action, it may be provided that the solid dosage form in the outer phase, in particular the capsule shell, as component (b) at least one mucilaginous drug, in particular marshmallow (Althaea officinalis L.), in an amount in the range of 0.001 up to 8% by weight, in particular in the range from 0.01 to 4% by weight, preferably in the range from 0.05 to 2% by weight, preferably in the range from 0.1 to 1.3% by weight , based on the composition contains.

In addition, it has proven to be advantageous if the solid dosage form in the outer phase, in particular the capsule shell, as component (b) at least one mucilage, in particular at least one carrageenan and / or its physiologically acceptable salts, in an amount in the range of 0 , 0001 to 2 wt .-%, in particular in the range of 0.001 to 1.5 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt. -%, based on the composition contains.

Moreover, as far as the further embodiment of the solid dosage form in the form of a multiphase system, it may be provided according to a preferred embodiment of the present invention, that the outer phase, in particular the capsule shell, and / or the inner phase, in particular the capsule core, at least one Sugar and / or sugar substitute.

It has proved to be advantageous if the at least one sugar is selected from the group of sucrose, glucose, in particular dextrose, and fructose. Equally, it can also be provided that the at least one sugar substitute is selected from the group of sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, particularly preferably isomalt and / or maltitol.

In the context of the present invention, it is also preferred if both the outer phase and the inner phase have sugars or sugar substitutes.

In this context, it may be provided in particular that the solid dosage form in the outer phase, in particular the capsule shell, at least one sugar and / or sugar substitute, in particular isomalt, in an amount in the range of 50 to 99 wt .-%, in particular in the range from 60 to 97 wt .-%, preferably in the range of 70 to 95 wt .-%, preferably in the range of 80 to 90 wt .-%, based on the composition contains.

In addition, it may be provided that the composition in the inner phase, in particular the capsule core, at least one sugar and / or sugar substitute, in particular maltitol, in an amount in the range of 1 to 50 wt .-%, in particular in the range of 2 to 25% by weight, preferably in the range of 5 to 20 wt .-%, preferably in the range of 7 to 10 wt .-%, based on the composition.

• (A) in der äußeren Phase, insbesondere der Kapselhülle, als Komponente (b) mindestens ein Carrageen und/oder dessen physiologisch verträgliche Salze in einer Menge im Bereich von 0,0001 bis 2 Gew.-%, insbesondere im Bereich von 0,001 bis 1,5 Gew.-%, vorzugsweise im Bereich von 0,01 bis 1 Gew.-%, bevorzugt im Bereich von 0,1 bis 0,5 Gew.-%, bezogen auf die Zusammensetzung; und Eibisch (Althaea officinalis L.), in einer Menge im Bereich von 0,001 bis 8 Gew.-%, insbesondere im Bereich von 0,01 bis 4 Gew.-%, vorzugsweise im Bereich von 0,05 bis 2 Gew.-%, bevorzugt im Bereich von 0,1 bis 1,3 Gew.-%, bezogen auf die Zusammensetzung; und
• (B) in der inneren Phase, insbesondere dem Kapselkern, als Komponente (a) mindestens einen aus Drosera, insbesondere Drosera rotundifolia, Drosera intermedia und/oder Drosera anglica, isolierten und/oder extrahierten Inhaltsstoff und/oder mindestens einen aus Drosera, insbesondere Drosera rotundifolia, Drosera intermedia und/oder Drosera anglica, gewonnenen Extrakt oder dessen Bestandteil in einer Menge im Bereich von 0,0001 bis 5 Gew.-%, insbesondere im Bereich von 0,001 bis 3 Gew.-%, vorzugsweise im Bereich von 0,01 bis 1 Gew.-%, bevorzugt im Bereich von 0,1 bis 0,5 Gew.-%, bezogen auf die Zusammensetzung; und als Komponente (b) mindestens ein Carrageen und/oder dessen physiologisch verträgliche Salze in einer Menge im Bereich von 0,0001 bis 1 Gew.-%, insbesondere im Bereich von 0,001 bis 0,5 Gew.-%, vorzugsweise im Bereich von 0,005 bis 0,1 Gew.-%, bevorzugt im Bereich von 0,01 bis 0,09 Gew.-%, bezogen auf die Zusammensetzung,

enthält. The present invention - according to a further preferred embodiment of the present invention - is thus a solid dosage form based on a multiphase system, wherein the solid dosage form in combination and in each case in effective, in particular pharmaceutically effective amounts

• (A) in the outer phase, in particular the capsule shell, as component (b) at least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 2 wt .-%, in particular in the range of 0.001 to 1 5% by weight, preferably in the range of 0.01 to 1% by weight, preferably in the range of 0.1 to 0.5% by weight, based on the composition; and marshmallow (Althaea officinalis L.), in an amount in the range of 0.001 to 8% by weight, in particular in the range of 0.01 to 4% by weight, preferably in the range of 0.05 to 2% by weight preferably in the range of 0.1 to 1.3% by weight, based on the composition; and
• (B) in the inner phase, in particular the capsule core, as component (a) at least one of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, isolated and / or extracted ingredient and / or at least one from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, extract or component thereof in an amount in the range of 0.0001 to 5 wt .-%, in particular in the range of 0.001 to 3 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition; and as component (b) at least one carrageenan and / or its physiologically acceptable salts in an amount in the range of 0.0001 to 1 wt .-%, in particular in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1% by weight, preferably in the range of 0.01 to 0.09% by weight, based on the composition,

contains.

According to yet another, equally preferred embodiment of the present invention, it may furthermore be provided that the composition is present as a liquid dosage form and / or that the composition is present as a fluid, mouthwash, mouthwash, juice, gargle solution or the like, in particular as juice. In particular, it may be provided in this connection that the liquid administration form is a cervical and / or cough syrup.

In order to ensure good efficacy, it is preferred according to the invention in this regard if the liquid dosage form contains the homeopathic active ingredient and / or component (a) in an amount in the range from 0.01 to 20% by weight, in particular in the range from 0, From 05 to 15% by weight, preferably in the range from 0.1 to 10% by weight, preferably in the range from 0.5 to 5% by weight, particularly preferably in the range from 0.7 to 2% by weight , based on the composition contains.

With regard to the selection of component (a) or of the homeopathic active ingredient, it has also surprisingly been found that a particularly good effectiveness is achieved when the homeopathic active ingredient and / or component (a) at least one from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, isolated and / or extracted ingredient or if the homeopathic active ingredient and / or component (a) is at least one extract obtained from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica Component is.

In the context of the present invention, it has surprisingly been found that the homeopathic active ingredient from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, in liquid compositions, in particular in combination with at least one mucilaginous or at least one mucilage, to an excellent efficacy in the context of the treatment of respiratory diseases, especially symptoms of colds. In particular, the coughing stimulus can be alleviated on this basis. Also, sore throat and hoarseness can be successfully treated.

As far as the at least one mucilage or the at least one mucilaginous drug as component (b) is concerned, it has proved to be particularly advantageous if, in the context of the present invention, the liquid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range of 0.1 to 30 wt .-%, in particular in the range of 0.5 to 20 wt .-%, preferably in the range of 1 to 15 wt .-%, preferably in the range of 5 to 13 wt .-%, based on the composition.

By using component (b) or the at least one mucilaginous drug and / or the at least one mucilage, an outstanding effectiveness of the compositions according to the invention in the form of liquid dosage forms is ensured.

With regard to the specific selection of component (b) for the liquid dosage form, it may be provided, in particular, that the liquid dosage form contains as component (b) at least one mucous drug, preferably a combination of two mucous drugs, in particular wherein the mucous drugs may be selected from Icelandic moss (Althaea officinalis L.) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.).

In the context of the present invention, it has surprisingly been found that, in particular, Icelandic moss and / or mallow lead to a further enhancement of the action of the homeopathic active substance. In particular, the anti-inflammatory and mucous membrane-wetting properties of the compositions according to the invention are further enhanced.

With regard to the quantities of component (b) used, it is preferred according to the invention if the liquid dosage form as component (b) contains Icelandic moss (Althaea officinalis L.) in an amount in the range from 0.01 to 20% by weight, in particular in the range from 0.1 to 15% by weight, preferably in the range from 1 to 10% by weight, preferably in the range from 3 to 7% by weight, based on the composition. Similarly, it may be contemplated that the liquid dosage form as component (b) mallow (Malva sylvestris L. and M. neglecta WALLR.) In an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0, 1 to 15 wt .-%, preferably in the range of 1 to 10 wt .-%, preferably in the range of 3 to 7 wt .-%, based on the composition contains. According to a particularly preferred embodiment, the composition according to the invention in the form of a liquid administration form as component (b) contains Icelandic moss and mallow in combination.

In addition, it has proven to be advantageous in terms of the effectiveness of the compositions according to the invention if the liquid dosage form contains at least one trace element and / or its physiologically acceptable salts. In this case, the at least one trace element and / or its physiologically acceptable salts from the group of chromium (Cr), cobalt (Co), iron (Fe), fluorine (F), iodine (I), copper (Cu), manganese (Mn ), Molybdenum (Mo), selenium (Se), silicon (Si) and / or zinc (Zn), preferably zinc, more preferably in the form of zinc gluconate.

As far as the amount of the at least one trace element used is concerned, this is variable. Particularly good results are achieved when the liquid dosage form comprises the at least one trace element in an amount in the range of 0.00001 to 10 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.01 to 0.1 wt .-%, based on the composition contains.

As far as the further embodiment of the composition according to the invention according to this further preferred embodiment is concerned, it may be provided that the liquid dosage form is aqueous, alcoholic or aqueous-alcoholic.

Moreover, in order to further improve the effectiveness of the composition according to the invention, it may be provided that the liquid dosage form contains the active ingredients and / or ingredients together with a harmless, in particular pharmacologically and / or physiologically acceptable carrier and / or excipient.

As regards the carrier in particular, it may be provided that it is selected from the group of solvents, solubilizers, emulsifiers and the like or that the carrier is selected from the group of water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol , Benzyl benzoate, propylene glycol, 1,3-butylglycol and combinations thereof.

In addition, it may be provided that the liquid dosage form comprises at least one sugar and / or sugar substitute. Preferably, the sugar may be selected from the group of sucrose, glucose, especially dextrose, and fructose. Similarly, it may be provided that the at least one sugar substitute is selected from sugar alcohols, preferably from the Group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, most preferably maltitol syrup.

Furthermore, it can also be provided that the liquid dosage form contains water, in particular in an amount of at least 10 wt .-%, in particular at least 20 wt .-%, preferably at least 30 wt .-%, based on the composition, and / or in particular in an amount in the range from 10 to 98% by weight, in particular in the range from 20 to 95% by weight, preferably from 30 to 90% by weight, based on the composition.

According to this embodiment of the present invention, there is thus provided a liquid dosage form based on at least one homeopathic active ingredient, in particular Drosera, preferably Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, on the one hand and at least one mucous drug, in particular Icelandic moss and mallow, on the other hand has an excellent efficacy in connection with the treatment of respiratory diseases, especially colds or influenza infections. The composition according to the invention in liquid dosage form leads to an excellent alleviation of the symptoms associated with cold sores, such as sore throat, hoarseness, cough and mucosal irritation.

• (a) mindestens einen aus Drosera, insbesondere Drosera rotundifolia, Drosera intermedia und/oder Drosera anglica, isolierten und/oder extrahierten Inhaltsstoff und/oder mindestens einen aus Drosera rotundifolia, Drosera intermedia und/oder Drosera anglica, gewonnenen Extrakt oder dessen Bestandteil in einer Menge im Bereich von 0,01 bis 20 Gew.-%, insbesondere im Bereich von 0,05 bis 15 Gew.-%, vorzugsweise im Bereich von 0,1 bis 10 Gew.-%, bevorzugt im Bereich von 0,5 bis 5 Gew.-%, besonders bevorzugt im Bereich von 0,7 bis 2 Gew.-%, bezogen auf die Zusammensetzung; und
• (b) Isländisch Moos (Althaea officinalis L.) in einer Menge im Bereich von 0,01 bis 20 Gew.-%, insbesondere im Bereich von 0,1 bis 15 Gew.-%, vorzugsweise im Bereich von 1 bis 10 Gew.-%, bevorzugt im Bereich von 3 bis 7 Gew.-%, bezogen auf die Zusammensetzung, und Malve (Malva sylvestris L. und M. neglecta WALLR.) in einer Menge im Bereich von 0,01 bis 20 Gew.-%, insbesondere im Bereich von 0,1 bis 15 Gew.-%, vorzugsweise im Bereich von 1 bis 10 Gew.-%, bevorzugt im Bereich von 3 bis 7 Gew.-%, bezogen auf die Zusammensetzung;

enthält. The present invention according to this aspect of the invention is therefore in particular a composition, as described above, in the form of a liquid dosage form, wherein the liquid dosage form in combination and in each case in effective, in particular pharmaceutically effective amounts

• (a) at least one extract obtained from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, and / or at least one extract obtained from Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, or its constituent in one Amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0.05 to 15 wt .-%, preferably in the range of 0.1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, particularly preferably in the range of 0.7 to 2 wt .-%, based on the composition; and
• (b) Icelandic moss (Althaea officinalis L.) in an amount in the range of 0.01 to 20% by weight, in particular in the range of 0.1 to 15% by weight, preferably in the range of 1 to 10% by weight. %, preferably in the range from 3 to 7% by weight, based on the composition, and mallow (Malva sylvestris L. and M. neglecta WALLR.) in an amount in the range from 0.01 to 20% by weight, in particular in the range of 0.1 to 15 wt .-%, preferably in the range of 1 to 10 wt .-%, preferably in the range of 3 to 7 wt .-%, based on the composition;

contains.

Finally, according to a further and equally preferred embodiment of the present invention, it may be provided that the composition is present as a spray and / or aerosol, in particular as a spray, preferably for nasal administration.

With regard to the homeopathic active ingredient or component (a), it has proven to be advantageous if the spray and / or aerosol the at least one homeopathic active ingredient and / or component (a) in an amount in the range of 0.001 to 5 wt .-%, in particular in the range of 0.005 to 3 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition , contains.

As regards the specific choice of component (a), particularly good results are achieved with regard to the effectiveness of the compositions when the at least one homeopathic active ingredient and / or component (a) contains at least one ingredient isolated and / or extracted from Galphimia glauca or if the homeopathic active ingredient and / or component (a) is at least one extract or its component derived from Galphimia glauca.

The efficiency of action of a composition based on a spray or aerosol according to the invention can be increased even further if the spray and / or aerosol contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range of 0.00001 to 1.5 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.8 wt .-%, preferably in the range of 0.1 to 0, 5 wt .-%, based on the composition contains.

With regard to the selection of component (b), particularly good results are also achieved if the spray and / or aerosol contains at least one mucilage as component (b).

According to a preferred embodiment, the at least one mucilage is hyaluronic acid or its physiologically tolerable salts.

Surprisingly, it has been found in the context of the present invention that based on the composition according to the invention in the form of a spray or aerosol, especially for nasal administration, with the active ingredient combination according to the invention at least one homeopathic active ingredient based on Galphimia glauca and the mucilage hyaluronic an excellent Efficacy in the treatment of respiratory diseases, particularly allergies. In particular, the symptoms associated with respiratory allergic diseases, such as runny nose, nasal congestion, coughing and sneezing attacks, and itching and watery eyes, can be alleviated with high efficiency.

In addition, the effectiveness or effectiveness of the composition according to the invention can be further increased if the spray and / or aerosol as further component (c) pantothenol, preferably dexpanthenol (D-pantothenol), or its physiologically acceptable esters and / or pantothenic acid or its physiological compatible salts.

Through the additional use of aerosol, the irritated and sometimes damaged nasal mucosa can be treated and cured or regenerated on the basis of the wound-healing-promoting properties of panthotenol or dexpanthenol and / or pantothenic acid.

As regards the amount of pantothenol or pantothenic acid used, it has proved to be advantageous if the spray and / or aerosol component (c) in an amount in the range of 0.01 to 20 wt .-%, in particular in the range from 0.1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, preferably in the range of 1 to 3 wt .-%, based on the composition.

In addition, it can be provided that the spray and / or aerosol contains as further component (d) at least one physiologically acceptable, osmotically active substance or at least one physiologically acceptable osmolyte.

As far as the selection of the osmolyte is concerned, the osmotically active substances and / or the osmolytes may in particular be selected from the group of ions of physiologically acceptable salts (ie salt ions), in particular alkali ions, in particular sodium ions and / or potassium Ions, and / or chloride ions, preferably sodium ions and chloride ions; Sugars, in particular trehalose and / or sucrose; Polyols, in particular glycerol; and / or amino acids, in particular glutamic acid and / or its physiologically tolerated salts, proline, (hydroxy) ectoine and / or glycine betaine.

According to a particularly preferred embodiment it can be provided that the osmotically active substances and / or the osmolytes are sodium ions and chloride ions, in particular in the form of sodium chloride.

Under osmotically active substances or osmolytes are usually understood substances that can affect the osmotic state of a system, in particular of cells.

By using osmotically active substances or osmolytes in the composition according to the invention, the composition can be provided on the basis of a hyperosmolar or hypoosmolar or isotonic solution. In the case of hyperosmolar or hypertonic compositions, which is preferred in the context of the present invention, a certain astringent effect of the composition according to the invention or decongestant effects can be achieved without the use of a downsweller, such as an alpha-sympathomimeticum, necessary , This is because the content of osmotically active substances or osmolytes, which is increased in relation to the cells of the nasal mucosa, removes excessively bound water from the cells of the nasal mucosa, so that the nasal mucous membrane swells and nasal breathing is improved. In addition, there is an improvement in the movement of the cilia, so that mucus and foreign bodies, such as pollen or dust, can be better removed. In combination with the optional additional use of pantothenol or pantothenic acid it is also possible to prevent hypertonic solutions in the context of the nasal administration according to the invention from causing the nasal mucosa to dry out.

As far as the amount of osmotically active substances or osmolytes used is concerned, it has proved to be particularly advantageous if the spray and / or aerosol contains component (d) in an amount in the range from 0.001 to 10% by weight, in particular Range of 0.01 to 5 wt .-%, preferably in the range of 0.1 to 3 wt .-%, preferably in the range of 1 to 2 wt .-%, based on the composition contains.

In addition, it can be provided in the context of the present invention that the spray and / or aerosol contains at least one acid and / or base, in particular for forming a buffer system. Likewise, it is possible that the composition contains at least one buffer system or that the composition preferably contains at least one base.

Furthermore, it is also preferred according to the invention if the spray and / or aerosol contains water. It has proved to be particularly advantageous if the spray or aerosol in an amount in the range of 80 to 99 wt .-%, preferably in the range of 85 to 98 wt .-%, preferably in the range of 90 to 97 Wt .-%, particularly preferably in the range of 93 to 96 wt .-%, based on the composition.

• (a) mindestens einen aus Galphimia glauca isolierten und/oder extrahierten Inhaltsstoff und/oder mindestens einen aus Galphimia glauca gewonnenen Extrakt oder dessen Bestandteil in einer Menge im Bereich von 0,001 bis 5 Gew.-%, insbesondere im Bereich von 0,005 bis 3 Gew.-%, vorzugsweise im Bereich von 0,01 bis 1 Gew.-%, bevorzugt im Bereich von 0,1 bis 0,5 Gew.-%, bezogen auf die Zusammensetzung;
• (b) mindestens einen Schleimstoff, insbesondere Hyaluronsäure und/oder deren physiologisch verträgliche Salze, in einer Menge im Bereich von 0,00001 bis 1,5 Gew.-%, insbesondere im Bereich von 0,0001 bis 1 Gew.-%, vorzugsweise im Bereich von 0,001 bis 0,8 Gew.-%, bevorzugt im Bereich von 0,1 bis 0,5 Gew.-%, bezogen auf die Zusammensetzung;
• (c) gegebenenfalls Pantothenol, vorzugsweise Dexpanthenol (D-Pantothenol), oder dessen physiologisch unbedenkliche Ester und/oder Pantothensäure oder deren physiologisch verträgliche Salze, in einer Menge im Bereich von 0,01 bis 20 Gew.-%, insbesondere im Bereich von 0,1 bis 10 Gew.-%, vorzugsweise im Bereich von 0,5 bis 5 Gew.-%, bevorzugt im Bereich von 1 bis 3 Gew.-%, bezogen auf die Zusammensetzung; und
• (d) gegebenenfalls mindestens einen physiologisch unbedenklichen bzw. verträglichen, osmotisch aktiven Stoff und/oder mindestens einen physiologisch unbedenklichen bzw. verträglichen Osmolyten in einer Menge im Bereich von 0,001 bis 10 Gew.-%, insbesondere im Bereich von 0,01 bis 5 Gew.-%, vorzugsweise im Bereich von 0,1 bis 3 Gew.-%, bevorzugt im Bereich von 1 bis 2 Gew.-%, bezogen auf die Zusammensetzung;

enthält. The present invention according to a further preferred embodiment according to the invention is thus a composition in the form of a spray or aerosol, wherein the spray and / or aerosol in combination and in each case in effective, especially pharmaceutically effective amounts

• (a) at least one ingredient isolated and / or extracted from Galphimia glauca and / or at least one extract derived from Galphimia glauca or its constituent in an amount in the range of 0.001 to 5 wt.%, in particular in the range of 0.005 to 3 wt. -%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition;
• (B) at least one mucilage, in particular hyaluronic acid and / or physiologically acceptable salts, in an amount in the range of 0.00001 to 1.5 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.8 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition;
• (c) optionally pantothenol, preferably dexpanthenol (D-pantothenol), or its physiologically acceptable ester and / or pantothenic acid or its physiologically acceptable salts, in an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0 From 1 to 10% by weight, preferably in the range from 0.5 to 5% by weight, preferably in the range from 1 to 3% by weight, based on the composition; and
• (D) optionally at least one physiologically acceptable or tolerable, osmotically active substance and / or at least one physiologically acceptable or compatible osmolyte in an amount in the range of 0.001 to 10 wt .-%, in particular in the range of 0.01 to 5 wt .-%, preferably in the range of 0.1 to 3 wt .-%, preferably in the range of 1 to 2 wt .-%, based on the composition;

contains.

In the context of the present invention, it has thus surprisingly been possible to provide a composition in the form of a spray and / or aerosol, in particular for nasal administration, which is distinguished by an outstanding efficiency of action with regard to the treatment of allergic respiratory diseases, but at least substantially none thereof Side effects, such as those associated with antihistamines or corticosteroids in particular.

In particular, excellent anti-allergic efficacy is achieved even without the additional use of corticosteroids and / or antihistamines.

The present invention thus also provides a composition as described above for use in the prophylactic and / or therapeutic treatment of respiratory diseases, in particular colds and / or allergies, in particular influenza infections, runny nose, cough, cold-related or allergic rhinitis, hoarseness and / or sore throat.

Furthermore, the present invention relates - according to another aspect - the use of a composition, as described above, in the prophylactic and / or therapeutic treatment of respiratory diseases, especially colds and / or allergies, especially influenza infections, runny nose, cough, cold-related or allergic rhinitis, hoarseness and / or sore throat.

For further details on the use according to the invention, reference may be made to the preceding statements relating to the other aspects of the invention, which apply correspondingly in relation to the use according to the invention.

Further embodiments, modifications and variations as well as advantages of the present invention will be readily apparent to and realizable by those skilled in the art upon reading the description without departing from the scope of the present invention.

The following embodiments are merely illustrative of the present invention, but without limiting the present invention thereto.

WORKING EXAMPLES

In order to investigate the efficacy of the compositions of the present invention, dosage forms of the present invention are provided in the form of lozenges, multi-phase lotion tablets, cough syrup and nasal spray and tested on subjects for efficacy.

1. lozenge with Arum triphyllum, carrageenans and hyaluronic acid

On the basis of the following formulation lozenges according to the invention with the active ingredient combination Arum triphyllum, carrageenans and hyaluronic acid are provided with the tabletting method known to the person skilled in the art. ingredient Amount [wt%] Carrageenan 0.2 Sodium hyaluronate 0.02 Arum triphyllum 0.001 mannitol 49.799 Flavors / Sweeteners 4.47 Other excipients 45.51

The homeopathic active ingredients based on Arum triphyllum are used in a dilution or potency of D6 compared to the mother tincture, wherein the mother tincture according to the usual rules, as described in the homeopathic pharmacopoeia, is produced. The preparation of the lozenges is carried out in a manner known to those skilled in the art, d. H. with respect to the merging of the ingredients and the subsequent tabletting no further comments are necessary at this point.

The tablets prepared in this way are tested to test their efficacy on 20 people aged 15 to 60 years suffering from influenza-type infections and associated symptoms, especially coughing and hoarseness. The subjects receive a lozenge four times a day, which is slowly sucked in the mouth. The treatment duration is five days.

In all persons who have taken the lozenge according to the invention for the treatment of cold symptoms, a significant improvement or relief of cold symptoms can be found. In particular, sore throat, irritable cough, hoarseness and inflammatory symptoms can be alleviated. Side effects are not observed in the subjects.

Overall, the compositions according to the invention in the form of lozenges with Arum triphyllum, carrageenans and hyaluronic acid as active ingredients are distinguished by their outstanding efficacy in the treatment of symptoms associated with influenza-like infections.

2. Two-phase lozenge with marshmallow root extract, carrageenans and Drosera

On the basis of the following formulation compositions of the invention in the form of two-phase lozenges with a combination of active ingredients based on marshmallow root, carrageenans and Drosera provided. The lozenges are provided by methods well known to those skilled in the art. ingredient Amount [wt%] capsule shell 90 hibiscus 1.0 Carrageenan 0.12 isomalt 86.9 Auxiliaries, flavors 1.93 capsule core 10 Carrageenan 0.06 Drosera 0.17 maltitol 8.4 Auxiliaries, flavors 1.4

 The two-phase lozenges according to the invention are provided by means of methods generally known to those skilled in the art for providing core / sheath capsules. The mother tincture of the homeopathic drug based on Drosera is provided in accordance with the usual provisions of the European Pharmacopoeia and adjusted to a dilution or potency of D6. The marshmallow root extract used has a drug / extract ratio of about 1: 1.

 In order to examine the effectiveness of the core / shell capsules according to the invention, 20 persons aged 15 to 60 who suffer from influenza-type infections and the associated symptoms, in particular dry, dry coughing and hoarseness, are consulted. The subjects receive a lozenge four times a day, which is slowly sucked in the mouth. The treatment duration is five days.

 After five days, the symptoms of cold, especially the cough and hoarseness, have improved significantly in all persons. The onset of action of the lozenges according to the invention is also extremely fast, i. already with the sucking of the first tablet, the subjects report an improvement of the acute symptoms, especially hoarseness. Furthermore, the composition is characterized by its excellent compatibility; No adverse reactions are documented for any subject.

The composition based on two-phase lozenges according to the invention are outstandingly suitable for the treatment of respiratory diseases, in particular influenza-like infections, or the associated symptoms. Without wishing to be limited to this theory, the combination of the mucin substance based on carrageenans and the mucous drug based on marshmallow root forms a protective layer on the mucous membrane, so that the mucous membrane can regenerate and, moreover, is shielded against further irritation. In addition, the used homeopathic drug Drosera has an anti-inflammatory effect.

3. Juice with Icelandic moss, mallow and drosera

On the basis of the following formulation compositions according to the invention are provided in the form of a juice with a combination of active ingredients based on Icelandic moss, mallow and Drosera. The juice is provided by methods known to those skilled in the art. ingredient Amount in% by weight Icelandic moss 4.67 mallow 4.67 Drosera 1.0 zinc gluconate 0.07 maltitol syrup 88.8 Auxiliaries and flavors 0.8

 The cress juice is provided on the basis of manufacturing processes known per se to those skilled in the art. The plant extracts used, d. H. Icelandic moss and mallow have a drug / extract ratio of 1: 1. In addition, the homeopathic drug based on Drosera is in potency D6 against the mother tincture.

 In order to check the efficacy of the juice of the present invention, children aged 5 to 12 years suffering from influenza, especially sore throat, irritable cough and hoarseness are treated three times a day with 20 ml of the half-juice each for 5 days.

 After five days, the symptoms of cold have improved greatly in all children. In particular, the cough is decreasing and sore throat can be effectively alleviated. Side effects are not observed in the subjects.

 As the foregoing shows, the juice of the present invention is distinguished by its excellent efficacy in the treatment of cold symptoms, especially sore throat, irritable cough and hoarseness.

4. Nasal spray with Galphimia glauca, hyaluronic acid and dexpanthenol

On the basis of the following formulation compositions of the invention are provided in the form of a nasal spray with a combination of active ingredients based on hyaluronic acid, dexpanthenol and Galphimia glauca. The nasal spray is provided by methods generally known to those skilled in the art. ingredient Amount in% by weight hyaluronic acid 0.02 Galphimia glauca 0.2 dexpanthenol 2.5 sodium chloride 1.3 buffer 0.923 water 95.057

 The used mother tincture of Galphimia glauca is obtained according to the usual regulations of the homeopathic pharmacopoeia and adjusted to a potency or dilution of D6 compared to the mother tincture.

 In order to investigate the effectiveness of the nasal spray according to the invention, persons aged 16 to 60 who suffer from allergic rhinitis caused by pollen and / or house dust are treated four times daily with the nasal spray according to the invention, wherein per spray unit a spray per nostril of the composition according to the invention is administered.

 In all treated subjects, the symptoms associated with allergic rhinitis are significantly alleviated. In particular, a swelling of the nasal mucosa can be achieved, so that the free nasal breathing is possible again. Furthermore, the nasal spray according to the invention has a positive effect on the wound healing of the inflamed and irritated nasal mucosa. Overall, the nasal spray according to the invention makes it possible to treat allergy-related symptoms without side effects and with high efficiency.

 On the basis of the nasal spray according to the invention, a highly effective and side effect-free composition is thus provided for the treatment of symptoms associated with respiratory allergic diseases.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited non-patent literature

• Römpp Chemie-Lexikon, 9th edition, volume 3, Georg Thieme Verlag, Stuttgart / New York, 1990, pages 2055/2056, keyword: "Icelandic moss" [0054]
• HagerROM 2001, Springer Verlag, Heidelberg, keywords: "Cetraria", "Cetraria ericetorum OPIZ", "Cetraria islandica (L.) ACHARIUS" and "Lichen islandicus (Icelandic moss)" [0054]
• Monograph "Lichen islandicus (Icelandic Moss)", Federal Gazette No. 43 of 2 March 1989 [0054]
• H. Wagner, "Pharmaceutical Biology - Drugs and their Ingredients", Gustav Fischer Verlag, Stuttgart / New York, 1985, page 281, keyword: "Cetrariae Lichen (= lichen islandicus - Icelandic moss)" [0054]

Claims (22)

Composition, in particular pharmaceutical composition, preferably for use in the prophylactic and / or therapeutic treatment of respiratory diseases, in particular colds and / or allergies, wherein the composition in combination and in each case in effective, in particular pharmaceutically effective amounts (a) at least one homeopathic active substance effective against colds and / or allergies ("component (a)"); and (b) at least one mucilaginous drug, in particular in the form of its extract and / or constituent (s), and / or at least one mucilage ("component (b)"); contains. Composition according to claim 1, wherein the homeopathic active ingredient and / or the component (a) is at least one ingredient isolated and / or extracted from plants, in particular wherein the plants are selected from the group of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galphimia glauca, and / or wherein the homeopathic active ingredient and / or component (a) is at least one plant-derived extract or its component, in particular where the plants are selected from the group of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, Arum triphyllum and / or Galphimia glauca; and or wherein the homeopathic active ingredient and / or the component (a) is used as a homeopathic mother tincture and / or wherein the homeopathic active ingredient and / or the component (a) in a decimal potency in the range of D1 to D30, in particular in the range of D2 to D15, is preferably used in the range of D3 to D10, preferably in the range of D4 to D7, based on the mother tincture of the homeopathic active ingredient; and or the composition comprising the homeopathic active ingredient and / or component (a) in an amount in the range of 0.00001 to 10% by weight, in particular in the range of 0.0001 to 5% by weight, preferably in the range of 0, 0005 to 4 wt .-%, preferably in the range of 0.0009 to 3 wt .-%, based on the composition contains; and or wherein the at least one mucilaginous drug is selected from the group of Icelandic moss (Lichen islandicus), marshmallow (Althaea officinalis L.), plantain (Plantago lanceolata L.), mallow (Malva sylvestris L. and M. neglecta WALLR.), fenugreek ( Trigonella foenum-graecum L.), salep and / or quince (Cydonia oblonga MILL.) And their combinations and mixtures, in particular from Icelandic moss (Lichen islandicus), marshmallow (Althaea officinalis L.) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.) as well as their combinations; and or wherein the mucus drug is marshmallow (Althaea officinalis L.) and / or Icelandic moss (Lichen islandicus) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.). A composition according to claim 1 or 2, wherein the at least one mucilaginous drug in the form of an extract, in particular a liquid extract and / or fluid extract, is used; and or wherein the at least one mucilaginous drug is used in the form of an aqueous, alcoholic or aqueous-alcoholic extract, in particular an alcoholic or aqueous-alcoholic extract; and or wherein the at least one mucilaginous drug in the form of an extract, in particular liquid extract, with a drug / extract ratio of at least 0.5: 1, in particular at least 0.6: 1, preferably at least 0.8: 1, particularly preferably at least 0.9 : 1 or more is used; and or wherein the at least one mucilaginous drug in the form of an extract, in particular liquid extract, with a drug / extract ratio in the range of 0.4: 1 to 15: 1, in particular in the range of 0.5: 1 to 10: 1, preferably in the range from 0.6: 1 to 8: 1, more preferably in the range of 0.8: 1 to 5: 1, most preferably in the range of 0.9: 1 to 3: 1, even more preferably of about 1: 1 , is used. Composition according to one of the preceding claims, wherein the at least one mucilage is selected from the group of carrageenans and / or their physiologically acceptable salts, hyaluronic acid and / or their physiologically acceptable salts, in particular Alkalihyaluronat, and / or xanthanes and / or their physiologically acceptable salts ; and / or wherein the composition comprises the at least one mucous drug and / or the at least one mucilage and / or component (b) in an amount in the range of 0.00001 to 30 wt .-%, in particular in the range of 0.0001 to 20 Wt .-%, preferably in the range of 0.005 to 15 wt .-%, preferably in the range of 0.001 to 10 wt .-%, based on the composition contains; and or wherein the composition contains at least one further active ingredient and / or ingredient, in particular selected from the group of (mucous) skin protection agents, antiseptics, local anesthetics, vitamins, trace elements, minerals, micronutrients and combinations thereof; and / or wherein the composition comprises at least one customary pharmaceutical additive and / or adjuvant, in particular selected from the group of processing aids, stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH adjusters, pH buffer substances, thickeners, flavorings, antiseptics, Colorants, buffers, fragrances, fragrances, stretchers, binders, wetting agents and / or preservatives and combinations thereof. A composition according to any one of claims 1 to 4, wherein the composition is in the form of a solid dosage form and / or wherein the composition is in the form of a tablet, dragee, pill, hard caramel or the like, in particular a lozenge, in particular the solid dosage form, in particular the lozenge Total weight in the range of 0.5 to 7 g, in particular in the range of 1 to 6 g, preferably in the range of 2 to 5 g; in particular, wherein the solid dosage form is formed such that the solid dosage form releases a therapeutically effective amount of the active ingredients and / or ingredients when sucking, when the solid dosage form is administered and sucked in the oropharynx of a patient; and or in particular wherein the solid dosage form comprises the active ingredients and / or ingredients in a solid matrix and / or mass, in particular in a matrix and / or mass based on sugars and / or sugar substitutes, in particular wherein the sugars are selected from the group of Sucrose, glucose, in particular dextrose, and fructose and / or in particular wherein the sugar substitutes are selected from sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructooligosaccharides, glucans, polyglucose, more preferably isomalt and / or mannitol; and or in particular wherein the solid dosage form of sugar and / or sugar substitutes in a relative amount in the range of 20 to 99 wt .-%, in particular in the range of 30 to 90 wt .-%, preferably in the range of 35 to 85 wt .-%, preferably in the range of 40 to 80 wt .-%, based on the composition. Composition according to Claim 5, wherein the solid dosage form comprises the at least one homeopathic active ingredient and / or the component (a) in an amount in the range of 0.000001 to 1 wt .-%, in particular in the range of 0.00001 to 0.5 wt .-%, preferably in the range of 0.0001 to 0.1 wt .-%, preferably in the range of 0.0005 to 0.01 wt .-%, particularly preferably in the range of 0.0009 to 0.005 wt .-%, based on the composition , contains; and or wherein the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range from 0.001 to 10% by weight, in particular in the range from 0.01 to 5% by weight. , preferably in the range of 0.05 to 2 wt .-%, preferably in the range of 0.1 to 1 wt .-%, particularly preferably in the range of 0.2 to 0.8 wt .-%, based on the composition , contains; and / or wherein the at least one homeopathic active ingredient and / or component (a) is at least one ingredient isolated and / or extracted from Arum triphyllum and / or wherein the homeopathic active ingredient and / or component (a) is at least one of Arum triphyllum Extract or its component is; and or wherein the solid dosage form contains as component (b) at least one mucilage, in particular wherein the at least one mucilage is selected from hyaluronic acid and / or their physiologically acceptable salts and / or carrageenans and / or their physiologically acceptable salts; and or wherein the solid dosage form contains as component (b) a combination of hyaluronic acid and / or physiologically acceptable salts thereof and at least one carrageenan and / or its physiologically acceptable salts, in particular wherein the solid dosage form contains hyaluronic acid and / or its physiologically acceptable salts in an amount in the Range of 0.00001 to 5 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, more preferably in the range of 0.01 to 0.05 wt .-%, based on the composition, and / or in particular wherein the solid dosage form at least one carrageenan and / or its physiologically acceptable salts in an amount in Range from 0.0001 to 20 wt .-%, in particular in the range of 0.001 to 10 wt .-%, preferably in the range of 0.01 to 5 wt .-%, preferably in the range of 0.05 to 2 wt. %, more preferably in the range of 0.1 to 1 Wt .-%, based on the composition contains. A composition according to claim 5 or 6, wherein the solid dosage form is in combination and in each case in effective, in particular pharmaceutically effective amounts (a) at least one ingredient isolated from Arum triphyllum and / or extracted and / or at least one extract obtained from Arum triphyllum or its constituent in an amount in the range of 0.00001 to 1% by weight, in particular in the range of 0.00005 to 0.5 wt .-%, preferably in the range of 0.0001 to 0.1 wt .-%, preferably in the range of 0.0005 to 0.01 wt .-%, particularly preferably in the range of 0.0009 to 0.005 wt .-%, based on the composition; and (b) hyaluronic acid and / or physiologically acceptable salts thereof in an amount in the range of 0.00001 to 5% by weight, in particular in the range of 0.0001 to 1% by weight, preferably in the range of 0.001 to 0, 5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, particularly preferably in the range of 0.01 to 0.05 wt .-%, based on the composition, and at least one carrageenan and / or its Physiologically acceptable salts in an amount in the range of 0.0001 to 20 wt .-%, in particular in the range of 0.001 to 10 wt .-%, preferably in the range of 0.01 to 5 wt .-%, preferably in the range of 0 From 05 to 2% by weight, more preferably in the range from 0.1 to 1% by weight, based on the composition; contains. A composition according to claim 5, wherein the solid dosage form is formed as a multiphase system having at least two different phases, in particular wherein the solid dosage form comprises an outer phase, in particular a capsule shell, and an inner phase, in particular a capsule core; in particular wherein the solid dosage form comprises the outer phase, in particular the capsule shell, in an amount in the range from 30 to 99% by weight, in particular in the range from 40 to 98% by weight, preferably in the range from 50 to 96% by weight preferably in the range of 60 to 95% by weight, more preferably in the range of 70 to 92% by weight, even more preferably in the range of 80 to 90% by weight, based on the composition; and or in particular wherein the solid dosage form comprises the inner phase, in particular the capsule core, in an amount in the range from 1 to 70% by weight, in particular in the range from 2 to 50% by weight, preferably in the range from 3 to 40% by weight, preferably in the range of from 5 to 30% by weight, more preferably in the range of from 7 to 20% by weight, even more preferably in the range of from 8 to 15% by weight, based on the composition; and or in particular wherein the solid dosage form contains the homeopathic active ingredient and / or the component (a) in the outer phase and / or in the inner phase, in particular in the inner phase, preferably in the capsule core; and or in particular wherein the solid dosage form comprises the at least one homeopathic active ingredient and / or component (a) in an amount in the range of 0.0001 to 5 wt .-%, in particular in the range of 0.001 to 3 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition contains, in particular wherein the solid dosage form the at least one homeopathic active ingredient and / or the component (a ) in the inner phase, in particular the capsule core. Composition according to Claim 8, wherein the at least one homeopathic active ingredient and / or component (a) is at least one of Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, isolated and / or extracted ingredient and / or wherein the homeopathic active ingredient and / or the component (a) at least one extract or its component derived from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica; and or wherein the solid dosage form contains component (b) in the outer phase and / or in the inner phase, preferably in the outer phase, in particular the capsule shell, and in the inner phase, in particular the capsule core; and or wherein the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range from 0.001 to 20% by weight, in particular in the range from 0.01 to 15% by weight, preferably in the range from 0.1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, particularly preferably in the range of 1 to 2 wt .-%, based on the composition, in particular wherein the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one mucilage in the outer phase, in particular the capsule shell, in an amount in the range from 0.001 to 10% by weight, in particular in the range from 0 , 01 to 5 wt .-%, preferably in the range of 0.05 to 2.5 wt .-%, preferably in the range of 0.1 to 1.5 wt .-%, based on the composition contains, and / / or in particular wherein the solid dosage form comprises component (b) and / or the at least one mucous drug and / or the at least one Schl eimstoff in the inner phase, in particular the capsule core, in an amount in the range of 0.0001 to 1 wt .-%, in particular in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, preferably in the range of 0.01 to 0.09 wt .-%, based on the composition contains. A composition according to claim 8 or 9, wherein the solid dosage form in the outer phase, in particular the capsule shell, as component (b) contains a combination of at least one mucus drug and at least one mucilage, in particular wherein the mucus drug is marshmallow (Althaea officinalis L.) and the mucilage at least one carrageenan and / or the physiologically acceptable salts thereof; and / or wherein the solid dosage form in the inner phase, in particular the capsule core, as component (b) contains at least one mucilage, in particular wherein the mucilage is at least one carrageenan and / or its physiologically acceptable salts; and / or wherein the solid dosage form in the outer phase, in particular the capsule shell, as component (b) at least one mucilaginous drug, in particular marshmallow (Althaea officinalis L.), in an amount in the range of 0.001 to 8 wt .-%, in particular Range of 0.01 to 4 wt .-%, preferably in the range of 0.05 to 2 wt .-%, preferably in the range of 0.1 to 1.3 wt .-%, based on the composition contains. A composition according to any one of claims 8 to 10, wherein the solid dosage form in the outer phase, in particular the capsule shell, as component (b) at least one mucilage, in particular at least one carrageenan and / or its physiologically acceptable salts, in an amount in the range of 0.0001 to 2 wt .-%, in particular in the range from 0.001 to 1.5% by weight, preferably in the range from 0.01 to 1% by weight, preferably in the range from 0.1 to 0.5% by weight, based on the composition ; and or wherein the outer phase, in particular the capsule shell, and / or the inner phase, in particular the capsule core, at least one sugar and / or Zuckerausstauschstoff, in particular wherein the at least one sugar is selected from the group of sucrose, glucose, in particular dextrose, and fructose and / or in particular wherein the at least one sugar substitute is selected from the group of sugar alcohols, preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, more preferably isomalt and / or maltitol; and or wherein the solid dosage form in the outer phase, in particular the capsule shell, at least one sugar and / or sugar substitute, in particular isomalt, in an amount in the range of 50 to 99 wt .-%, in particular in the range of 60 to 97 wt .-%, preferably in the range of 70 to 95% by weight, preferably in the range of 80 to 90% by weight, based on the composition; and or wherein the composition in the inner phase, in particular the capsule core, at least one sugar and / or sugar substitute, in particular maltitol, in an amount in the range of 1 to 50 wt .-%, in particular in the range of 2 to 25 wt .-%, preferably in the range of 5 to 20 wt .-%, preferably in the range of 7 to 10 wt .-%, based on the composition. A composition according to any one of claims 8 to 11, wherein the solid dosage form is in combination and in each case in effective, in particular pharmaceutically effective amounts (A) in the outer phase, in particular the capsule shell, as component (b) at least one carrageenan in an amount in the range of 0.0001 to 2 wt .-%, in particular in the range of 0.001 to 1.5 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range from 0.1 to 0.5% by weight, based on the composition; and Marshmallow (Althaea officinalis L.), in an amount in the range of 0.001 to 8% by weight, in particular in the range of 0.01 to 4% by weight, preferably in the range of 0.05 to 2% by weight, preferably in the range of 0.1 to 1.3 wt .-%, based on the composition; and (B) in the inner phase, in particular the capsule core, as component (a) at least one extract isolated from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, and / or at least one extract obtained from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, or its component in one Amount in the range of 0.0001 to 5 wt .-%, in particular in the range of 0.001 to 3 wt .-%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0, 5% by weight, based on the composition; and as component (b) at least one carrageenan in an amount in the range of 0.0001 to 1 wt .-%, in particular in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.005 to 0.1 wt .-%, preferably in the range from 0.01 to 0.09% by weight, based on the composition, contains. A composition according to any one of claims 1 to 4, wherein the composition is in the form of a liquid dosage form and / or the composition being in the form of a fluid, mouthwash, mouthwash, juice, gargle solution or the like, especially as a juice; in particular wherein the liquid dosage form comprises the homeopathic active ingredient and / or component (a) in an amount in the range from 0.01 to 20% by weight, in particular in the range from 0.05 to 15% by weight, preferably in the range from 0.1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, particularly preferably in the range of 0.7 to 2 wt .-%, based on the composition contains; and / or in particular wherein the homeopathic active ingredient and / or component (a) is at least one ingredient isolated and / or extracted from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, and / or wherein the homeopathic active ingredient and / or the component (a) is at least one extract obtained from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, or its component; and / or in particular wherein the liquid dosage form contains component (b) and / or the at least one mucous drug and / or the at least one mucilage in an amount in the range from 0.1 to 30% by weight, in particular in the range from 0.5 to 20 wt .-%, preferably in the range of 1 to 15 wt .-%, preferably in the range of 5 to 13 wt .-%, based on the composition contains; and / or in particular wherein the liquid dosage form contains as component (b) at least one mucilaginous drug, preferably a combination of two mucous drugs, in particular wherein the mucous drugs are selected from Icelandic moss (Althaea officinalis L.) and / or mallow (Malva sylvestris L. and M. neglecta WALLR.); and / or in particular wherein the liquid dosage form as component (b) Icelandic moss (Althaea officinalis L.) in an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0.1 to 15 wt .-% preferably in the range of 1 to 10% by weight, preferably in the range of 3 to 7% by weight, based on the composition; and / or in particular wherein the liquid dosage form as component (b) mallow (Malva sylvestris L. and M. neglecta WALLR.) In an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0.1 to 15 wt .-%, preferably in the range of 1 to 10 wt .-%, preferably in the range of 3 to 7 wt .-%, based on the composition contains. A composition according to claim 13, wherein the liquid dosage form contains at least one trace element and / or its physiologically acceptable salts, in particular wherein the at least one trace element and / or its physiologically tolerable salts is selected from the group of chromium (Cr), cobalt (Co), Iron (Fe), fluorine (F), iodine (I), copper (Cu), manganese (Mn), molybdenum (Mo), selenium (Se), silicon (Si) and / or zinc (Zn), preferably zinc, particularly preferably in the form of zinc gluconate, and / or in particular wherein the liquid dosage form contains the at least one trace element in an amount in the range from 0.00001 to 10% by weight, in particular in the range from 0.0001 to 1% by weight. %, preferably in the range of 0.001 to 0.5 wt .-%, preferably in the range of 0.01 to 0.1 wt .-%, based on the composition contains; and / or wherein the liquid dosage form is aqueous, alcoholic or aqueous-alcoholic; and / or wherein the liquid dosage form contains the active ingredients and / or ingredients together with a harmless, in particular pharmacologically and / or physiologically acceptable carrier and / or excipient, in particular wherein the carrier is selected from the group of solvents, solubilizers, emulsifiers and the like in particular wherein the carrier is selected from the group of water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol and combinations thereof; and / or wherein the liquid dosage form comprises at least one sugar and / or sugar substitute, in particular wherein the at least one sugar is selected from the group of sucrose, glucose, in particular dextrose, and fructose and / or in particular wherein the at least one sugar substitute is selected from sugar alcohols , preferably from the group of mannitol, xylitol, sorbitol, isomalt, maltitol syrup, lactitol, leucrose, fructo-oligosaccharides, glucans, polyglucose, most preferably maltitol syrup; and / or wherein the liquid dosage form contains water, in particular in an amount of at least 10 wt .-%, in particular at least 20 wt .-%, preferably at least 30 wt .-%, based on the composition, and / or in particular in an amount in the range of 10 to 98 wt .-%, in particular in the range 20 to 95 wt .-%, preferably 30 to 90 wt .-%, based on the composition. A composition according to any one of claims 13 or 14, wherein the liquid dosage form is in combination and in each case in effective, in particular pharmaceutically effective amounts (a) at least one extract isolated from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica, and / or at least one extract obtained from Drosera, in particular Drosera rotundifolia, Drosera intermedia and / or Drosera anglica Ingredient in an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0.05 to 15 wt .-%, preferably in the range of 0.1 to 10 wt .-%, preferably in the range of 0 From 5 to 5% by weight, more preferably in the range from 0.7 to 2% by weight, based on the composition; and (b) Icelandic moss (Althaea officinalis L.) in an amount in the range of 0.01 to 20% by weight, in particular in the range of 0.1 to 15% by weight, preferably in the range of 1 to 10% by weight. -%, preferably in the range of 3 to 7 wt .-%, based on the composition, and Mallow (Malva sylvestris L. and M. neglecta WALLR.) In an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0.1 to 15 wt .-%, preferably in the range of 1 to 10 Wt .-%, preferably in the range of 3 to 7 wt .-%, based on the composition; contains. A composition according to any one of claims 1 to 4, the composition being present as a spray and / or aerosol, in particular as a spray, preferably for nasal administration; in particular wherein the spray and / or aerosol contains the at least one homeopathic active ingredient and / or component (a) in an amount in the range from 0.001 to 5% by weight, in particular in the range from 0.005 to 3% by weight, preferably in the range from 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition contains; and or in particular wherein the at least one homeopathic active ingredient and / or component (a) is at least one ingredient isolated and / or extracted from Galphimia glauca and / or wherein the homeopathic active ingredient and / or component (a) is at least one extract derived from Galphimia glauca or whose component is. A composition according to claim 16, wherein the spray and / or aerosol contains component (b) and / or the at least one mucilaginous drug and / or the at least one mucilage in an amount in the range of 0.00001 to 1.5% by weight, in particular in the range of 0, 0001 to 1 wt .-%, preferably in the range of 0.001 to 0.8 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition contains; and or wherein the spray and / or aerosol contains as component (b) at least one mucilage, in particular wherein the at least one mucilage hyaluronic acid and / or their physiologically acceptable salts; and or wherein the spray and / or aerosol as further component (c) pantothenol, preferably dexpanthenol (D-pantothenol), or its physiologically acceptable esters and / or pantothenic acid or its physiologically acceptable salts, contains, in particular wherein the spray and / or aerosol, the component (C) in an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0.1 to 10 wt .-%, preferably in the range of 0.5 to 5 wt .-%, preferably in the range from 1 to 3 wt .-%, based on the composition contains. A composition according to claim 15 or 16, wherein the spray and / or aerosol contains as further component (d) at least one physiologically compatible, osmotically active substance and / or at least one physiologically acceptable osmolyte, in particular wherein (d) the osmotically active substances and / or the osmolytes are selected from the group of ions of physiologically acceptable salts (ie salt ions), in particular alkali ions, in particular sodium ions and / or potassium ions, and / or chloride ions, preferably sodium ions and chloride ions; Sugars, in particular trehalose and / or sucrose; Polyols, in particular glycerol; and / or amino acids, in particular glutamic acid and / or its physiologically tolerated salts, proline, (hydroxy) ectoine and / or glycine betaine, and / or in particular wherein the osmotically active substances and / or the osmolytes are sodium ions and chloride ions, in particular in the form of sodium chloride, and / or in particular wherein the spray and / or aerosol component (d) in an amount in the range of 0.001 to 10 wt .-%, in particular in the range of 0.01 to 5 wt .-%, preferably in the range of 0.1 to 3 Wt .-%, preferably in the range of 1 to 2 wt .-%, based on the composition contains. A composition according to any one of claims 16 to 18, wherein the spray and / or aerosol contains at least one acid and / or base, in particular for forming a buffer system, and / or wherein the composition contains at least one buffer system and / or wherein the composition preferably at least one Base contains; and / or wherein the spray and / or aerosol contains water, in particular in an amount in the range from 80 to 99% by weight, preferably in the range from 85 to 98% by weight, preferably in the range from 90 to 97% by weight. %, more preferably in the range of 93 to 96 wt .-%, based on the composition. A composition according to any one of claims 16 to 19, wherein the spray and / or aerosol in combination and in each case in effective, especially pharmaceutically effective amounts (a) at least one ingredient isolated and / or extracted from Galphimia glauca and / or at least one extract derived from Galphimia glauca or its constituent in an amount in the range of 0.001 to 5 wt.%, in particular in the range of 0.005 to 3 wt. -%, preferably in the range of 0.01 to 1 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition; (B) at least one mucilage, in particular hyaluronic acid and / or physiologically acceptable salts, in an amount in the range of 0.00001 to 1.5 wt .-%, in particular in the range of 0.0001 to 1 wt .-%, preferably in the range of 0.001 to 0.8 wt .-%, preferably in the range of 0.1 to 0.5 wt .-%, based on the composition; (c) optionally pantothenol, preferably dexpanthenol (D-pantothenol), or its physiologically acceptable ester and / or pantothenic acid or its physiologically acceptable salts, in an amount in the range of 0.01 to 20 wt .-%, in particular in the range of 0 From 1 to 10% by weight, preferably in the range from 0.5 to 5% by weight, preferably in the range from 1 to 3% by weight, based on the composition; and (D) optionally at least one physiologically acceptable or tolerable, osmotically active substance and / or at least one physiologically acceptable or compatible osmolyte in an amount in the range of 0.001 to 10 wt .-%, in particular in the range of 0.01 to 5 wt .-%, preferably in the range of 0.1 to 3 wt .-%, preferably in the range of 1 to 2 wt .-%, based on the composition; contains. Composition according to one of the preceding claims for use in the prophylactic and / or therapeutic treatment of respiratory diseases, in particular colds and / or allergies, in particular flu-like infections, runny nose, cough, cold-related or allergic rhinitis, hoarseness and / or sore throat. Use of a composition according to any one of the preceding claims in the prophylactic and / or therapeutic treatment of respiratory diseases, especially colds and / or allergies, especially flu, cold, cough, cold or allergic rhinitis, hoarseness and / or sore throat.